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Abstract 
Worldwide antibiotic resistance among oral microbiota is an increasing problem and 
information regarding such resistance is completely lacking for Yemen and very lim-
ited data is available for Norway. The aims of the current thesis were to (1) disclose 
the prevalence of ampicillin and metronidazole resistance among selected subgingival 
microbial species obtained from individuals in Yemen and Norway (paper 1), (2) 
determine the susceptibility pattern of Fusobacterium nucleatum isolated from 
Yemen and characterize the aminopenicillins-resistance determinant of F. nucleatum 
(paper 2), and (3) assess if antimicrobial prescription practices by dentists in Yemen 
and Norway could possibly contribute to the current prevalence and the emergence of 
bacterial resistance in these geographically separate locations (papers 3 and 4). 
Materials: Thirty-four and 21 subgingival plaque samples from Yemen and Norway, 
respectively, were cultivated on fastidious anaerobic blood agar containing 2 µg/mL 
of either ampicillin or metronidazole. The bacterial growth from each plate was then 
screened using DNA-DNA checkerboard hybridization technique for the presence of 
ampicillin and metronidazole resistance among 18 selected subgingival species 
(paper 1). Ampicillin-resistant F. nucleatum strains were isolated from Yemen by 
cultivating subgingival plaque samples on crystal violet erythromycin (CVE) plates 
supplemented with or without 2 µg/mL ampicillin. The molecular basis of ampicillin 
resistance among F. nucleatum strains was studied using two-dimensional gel electro-
phoresis and mass spectrometry (paper 2).The antimicrobials prescription knowledge 
of Yemeni dentists was investigated by distributing a structured questionnaire to all 
working dentists in the three major governorates in Yemen. The questionnaire aimed 
at investigating the therapeutic and prophylactic use of antimicrobials with relevant 
clinical and non-clinical parameters (paper 3). The Norwegian dentists’ antimicrobial 
prescription practices were revealed by analyzing aggregated data obtained from the 
Norwegian Prescription Database (NorPD) on the basis of their total prescriptions of 
11 antibiotics issued in 2004 and 2005. Consumptions of these antibiotics in dental 
practice were measured using the WHO measurement unit, the Defined Daily Dose 
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(DDD) (paper 4). Results: A statistically significant higher resistance to metronida-
zole and ampicillin among nine and seven species (P <0.05), respectively, was found 
in Yemeni isolates compared with Norwegian ones. The molecular characterization 
of ampicillin-resistant F. nucleatum isolates showed that ampicillin-resistant F. 
nucleatum isolates harboured a class D β-lactamase enzyme. In addition, increased 
synthesis of two proteins, enolase and ABC transporter ATP-binding proteins, was 
associated with β-lactamase enzyme production. A sound knowledge of antimicrobi-
als prescription among Yemeni dentists was lacking with a trend of overuse. NorPD 
data showed antimicrobial prescribing trend in favour of narrow-spectrum penicillins 
among Norwegian dentists. Conclusions:  The findings indicate that high prevalence 
of resistance among oral bacteria in Yemen maybe a potential threat in the manage-
ment of dental infections in the region. Antimicrobial overuse by dentists in Yemen 
could exacerbate the existing dilemma of antimicrobial resistance of oral bacteria. In 
contrast, the low prevalence of resistance among subgingival species in Norway is 
most probably a result of the judicious use of antimicrobials, that is, more restrictive 
prescribing practices in the country. The presence of class D β-lactamase among am-
picillin-resistant F. nucleatum strains increases their virulence and cost of treatments 
as these enzymes might present resistance to several classes of β-lactam antibiotics. 
Recommendations: Halting resistance development and saving effectiveness of an-
timicrobials need strict, practical, and feasible approaches. There is an urgent need to 
formulate an action plan to counter the revealed situation of antimicrobial resistance 
in Yemen. A proposed strategy to be adopted in the country for the control of antim-
icrobial resistance should be based on the prevention of communicable diseases and 
infection control to reduce the need for antimicrobial agents. An antimicrobial resis-
tance surveillance system and a multidisciplinary committee that monitors antimicro-
bial use in the country should form integral parts of a structured approach to reduce 
antimicrobial resistance by improving antimicrobial prescribing. Finally, such an ef-
fective strategy requires close cooperation and consultation between Yemen and 
other involved parties, both at national and international levels. 
                                                                                  Oral bacterial resistance 
 
7
1. Introduction 
1.1 Oral microbiota  
The oral cavity is the first part of the gastrointestinal tract and it has a number of fea-
tures that makes it a distinct microbial habitat. The various surfaces in the oral cavity 
are continuously bathed with saliva and they represent different ecological niches in 
which distinct inhabitants exist within this complex environment. The ecological 
characteristics of the different surfaces found in the oral cavity, each with different 
key ecological factors such as adhesion ligands, pH, nutrients, redox potential, 
oxygen tension, and temperature, make it a unique microbial habitat in the human 
body [1]. The composition of microbiota in the oral cavity is complex and such 
complicity was noticed in as early as 1683 by Antonie van Leeuwenhoek [2]. The 
oral microbiota is composed predominantly of bacteria, but fungi, viruses, 
mycoplasmas, and even protozoa and archaea can be found. It is estimated that more 
than 700 cultivable and noncultivable species are present in the oral cavity [3]. Over 
400 of the 700 oral species have been identified from the periodontal pocket and 300 
species from other locations in the oral cavity. Any particular individual is thought to 
have approximately 100–200 of these 700 species and is thought to harbour around 
50 species in the periodontal pocket [4].  
Several Gram-positive and Gram-negative bacterial genera are found in the 
oral cavity. Among the Gram-positive ones are Enterococcus, Peptostreptococcus, 
Streptococcus, Staphylococcus, Actinomyces, Corynebacterium, Eubacterium, and 
Lactobacillus species, whereas Aggregatibacter (formerly Actinobacillus), 
Haemophilus, Bacteroides, Campylobacter, Leptotrichia, Prophyromonas, 
Capnocytophaga, Prevotella, Tannerella, Eikenella, Treponema, Fusobacterium, and 
Wolinella species are among the Gram-negative ones [1].  
Adhesion of bacteria species to oral surfaces is the initial event in their estab-
lishment as a distinct microbial community in different niches within the oral cavity. 
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The initial adhesion is characterized by the presence of the same bacterial species that 
later on may modify the surrounding environment, making it suitable for other 
species to colonize [1].   
 Despite the diverse community of microorganisms found within the oral 
cavity, it is characterized by a high degree of stability. Such a stable community is 
referred to as climax community [1].  It is maintained in spite of host defence and 
modest environmental stress, such as, changes in saliva flow, diets, regular exposure 
to mouth rinses and tooth pastes, challenge by exogenous species, and exposure to 
antimicrobials. This stability, referred to as microbial homeostasis, is of great 
importance to oral health as it insures that potentially harmful species remain in low 
numbers [1]. Major environmental perturbations, such as pH or redox potential 
changes, are necessary to break the microbial homeostasis, resulting in deteriorated 
oral health and development of diseases, such as periodontitis and dental caries [5]. 
Dental plaque and oral diseases 
Coaggregation is the physical interaction between bacteria of different species. It is 
not random among oral bacteria; each species binds specifically to other bacteria. The 
diverse community of microorganisms found on a tooth surface is known as dental 
plaque. It is defined clinically as the soft, tenacious deposit that forms on tooth sur-
faces that is not readily removed by rinsing with water [6]. Microbiologically, it can 
be defined as the diverse community of microorganisms found on a tooth surface as a 
biofilm, embedded in an extracelluar matrix of polymers of host, and is of microbial 
origin [7]. Recently, the classical name of bacterial deposits on tooth surfaces known 
as “dental plaque” is increasingly substituted by the more appropriate name “dental 
biofilm”. According to its location, dental biofilm can be found supragingivally or 
subgingivally. The general properties of a biofilm make the involved microorganisms 
dramatically different from their planktonic counterparts, that is, bacteria that are sus-
pended or growing in a fluid. Such properties include open architecture, protection 
from host defences, enhanced resistance to antimicrobial agents, neutralization of in-
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hibitors, novel gene expression, coordinated gene responses, spatial and environ-
mental heterogeneity, broader habitat range, and more efficient metabolism [7].  
It is well known that periodontal diseases [8] and dental caries, the most 
prevalent microbial diseases in humans, are dental biofilm-mediated diseases [2, 9]. 
There has been an ongoing controversy as to which bacteria or bacterial species 
within the dental biofilm are involved in the causation of these diseases. The issue is 
even more complicated in the case of periodontal diseases, principally because these 
diseases occurs at sites with a preexisting complex normal flora, making discrimina-
tion of opportunistic pathogens from host-compatible species a real challenge, espe-
cially the fact that the pathogens may be carried in low numbers in a healthy oral cav-
ity [10, 11]. In addition, periodontal infections seem to be mixed in nature, involving 
more than one bacterial species, rendering evaluation of the aetiology of periodontitis 
a difficult task. For this and others reasons, Koch’s postulates have been replaced by 
a set of criteria to define periodontal pathogens. These criteria include (1) association 
(the species is found more frequently and at higher levels in disease compared to 
health), (2) elimination (elimination of the species is paralleled by remission of dis-
ease), (3) host response (presence of immune response against that species), (4) pos-
session of virulence factors, and (5) induction of disease in animals [10]. These crite-
ria assisted researches in pointing out some candidates as etiological agents of perio-
dontal diseases. In light of these criteria, there was a strong evidence to support a 
consensus implicating Porphyromonas gingivalis and Tannerella forsythia as 
etiological agents of chronic periodontitis, and Aggregatibacter 
actinomycetemcomitans as that of aggressive periodontitis [12]. 
It is well known that in dental biofilm, certain bacteria often cluster together 
and if one member of a particular cluster is detected in a sample, other members of 
that cluster are also most likely to be detected [13], indicating that these bacteria pre-
fer similar living environment. There are five microbial complexes described, 
namely, red, orange, yellow, purple, and green complexes, in subgingival plaque 
[13]. The red complex is composed of P. gingivalis, T. forsythia and Treponema 
denticola, and it is strongly associated with the clinical signs of chronic periodontitis, 
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whereas bacteria of the genera Fusobacterium, Prevotella, Peptostreptococcus, 
Eubacterium, and Campylobacter, which are members of the orange complex, are 
moderately associated with the disease.  
Fusobacterium nucleatum 
The Fusobacterium species is an old genus and currently includes 13 species from 
both human and animals [14-16]. Fusobacterium nucleatum species are most fre-
quently isolated from the oral cavity. The bacterium is an anaerobic, nonsporing, 
nonmotile and Gram-negative rod bacterium with fused ends [17]. The heterogeneity 
of F. nucleatum is well known and five subspecies of F. nucleatum have been de-
scribed [14, 15, 18]. The taxonomy of F. nucleatum subspecies is on a shaky ground, 
as there seems to be much heterogeneity within this species [19, 20]. The five de-
scribed F. nucleatum subspecies are: F. nucleatum subspecies nucleatum, F. 
nucleatum subspecies vincentii, F. nucleatum subspecies polymorphum, F. nucleatum 
subspecies fusiforme and F. nucleatum subspecies animalis. All F. nucleatum subspe-
cies are human isolates except F. nucleatum subspecies animalis which is of animal 
origin [14, 15]. 
F. nucleatum can be encountered in their niches within the oral cavity in the 
early months of life [21]. It acts as a bridge between early and late colonizers in 
dental plaque and coaggregates with many species found in the oral cavity including 
periodontal pathogens [22-25]. The proportion and number of F. nucleatum isolates 
are higher in individuals with compromised periodontal tissues. During periodontal 
infections, the cell mass of F.nucleatum increases as much as 10,000-fold, making it 
one of the most abundant anaerobic species in the disease sites [26]. However, the 
actual role of F. nucleatum in periodontal disease pathogenesis is probably masked 
by the bacterium being a common isolate in healthy individuals also [11]. In addition, 
virulence factors of F. nucleatum are less studied than those in other bacteria known 
as etiological factors of periodontal diseases. The pathogenic role of F. nucleatum in 
otitis media, orofacial and skin infections, tonsillar abscesses, septic arthritis, and 
bacterial endocarditis has been documented [17, 27]. 
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 The genome of both F. nucleatum subspecies nucleatum type strain ATCC 
25586 and F. nucleatum subspecies vincentii type strain ATCC 49256 has been pub-
lished [28] [29]. The genome of F. nucleatum subspecies nucleatum (ATCC 25586) 
contains 2.17 Mbp encoding 2067 open reading frames (ORFs) and its comparison 
with F. nucleatum subspecies vincentii (ATCC 49256) underscores the heterogeneity 
of F. nucleatum subspecies [29]. Despite the fact that F. nucleatum is a Gram-nega-
tive bacterium, interesting phylogenetic inferences, based on conserved indels (i.e. 
protein domain(s) insertion and deletion), place it at an intermediate position between 
Gram-positive and Gram-negative taxa [30]. In line with this, based on 16S rRNA 
sequence analysis, Fusobacterium species appear as a separate cluster only distantly 
associated to the low G+C Gram-positive bacteria [18, 31].  
Strains of F. nucleatum are intrinsically resistant to erythromycin. Thus, eryth-
romycin is used in the selective medium for isolation of F. nucleatum in plaque sam-
ples [32]. Most strains of F. nucleatum are susceptible to penicillin, but an ongoing 
increase in the proportions of F. nucleatum isolates resistant to penicillins have been 
reported [33, 34]. β-Lactamase enzyme production was detected in penicillin resistant 
F. nucleatum species [34-36].  
1.2  Antibiotics and antimicrobials  
The word antibiotic originally described a substance, such as penicillin or cepha-
losporin, produced by or derived mostly from certain fungi, bacteria, and other or-
ganisms, that can directly kill or inhibit the growth of other microorganisms. Later, 
these substances were replaced by synthetic or semisynthetic derivatives that were 
designated antimicrobials or microbial agents to distinguish them from the former. 
However, nowadays, the term antibiotic is often used informally for a drug that ac-
cording to this definition is an antimicrobial. In the present thesis, both terms will be 
used synonymously for antibacterial agents.  
         Mohammed Al-Haroni                                                                                      
 
12
The first antibiotic, penicillin, was discovered in 1928 by Sir Alexander 
Fleming. Ten years after the Fleming’s discovery of penicillin, sulfonamide was dis-
covered, and as time passed, new drug discoveries led to an explosive development of 
numerous antibiotics from the 1950s till the early 1990s. It was not surprising that 
shortly after numerous antibiotic discoveries that were active against both Gram-
positive and Gram-negative bacteria, surgeons believed at that time that the ongoing 
ancient fight between human and infectious diseases was becoming to an end.    
The antimicrobial agents can be divided into two major groups: bactericidal 
agents, which kill bacteria; and bacteriostatic agents, which inhibit bacterial multipli-
cation without actually killing them. It is found that these agents inhibit the growth of 
or kill microorganisms by a variety of mechanisms. In general, their action on 
bacteria involves cell wall, ribosomes, cytoplasmic membrane and nucleic acid 
replication sites.  
Antibiotics in dental practice  
It is well known that periodontitis and dental caries are dental biofilm-mediated dis-
eases [2, 9]. Therefore, reduction of dental biofilm accumulation is regarded a pre-
mium goal in controlling these diseases. This is achieved mainly by patient’s oral hy-
giene efforts with regular professional help by dental hygienists. Systemic antibiotic 
therapy has no effect on reducing supragingival plaque accumulation and solely dedi-
cating them to control the dental plaque-mediated periodontal diseases is not an ap-
propriate practice [37]. Mechanical debridement of dental biofilm alone is usually, 
but not always, sufficient for the control of these diseases. Therefore, chemotherapy 
is sometimes needed to aid the mechanical debridement.  
Dental practitioners, by law, have the right to prescribe a battery of antibiotics in 
dental practice. In general, antimicrobial prescribing in dental clinics are justified as: 
(1) therapeutic aid to surgical treatment of an acute or chronic infection, (2) therapeu-
tic to treat active infectious disease, for example, acute ulcerative gingivitis, and (3) 
prophylactic to prevent metastatic infection, such as bacterial endocarditis [38-42]. It 
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is worth mentioning in this respect that prophylaxis in medically compromised pa-
tients (MCPs) who receive dental treatment is not always a clear-cut matter, because 
different guidelines may have different recommendations and various regimens exist. 
Furthermore, these guidelines are always under revision and, therefore, dentists are 
required to update themselves regularly. Just recently, the American Heart Associa-
tion (AHA) recommends that some patients who have taken prophylactic antibiotics 
routinely in the past are no longer in need of prophylactic antibiotics as a preventive 
measure before their dental treatment. This includes patients with mitral valve 
prolapse, rheumatic heart disease, bicuspid valve disease, calcified aortic stenosis, 
and congenital heart conditions such as ventricular septal defect, atrial septal defect, 
and hypertrophic cardiomyopathy [43]. Clinical signs and symptoms of active 
infections include tachycardia, facial swelling, limited mouth opening, raised 
temperature, difficulty in swallowing, and regional lymphadenitis. Single or 
combined drug therapies have gained increasing importance in dental practice, but, 
whenever possible, single drug therapy should be prescribed to reduce incidence of 
side effects, emergence of resistance, and the cost of therapy. 
 Antibiotic prescription should be based on microbiological testing for the fol-
lowing clinical diagnosis: aggressive periodontitis, generalized severe chronic perio-
dontitis, periodontitis exhibiting progressive attachment loss despite thorough ade-
quate treatment, and severe periodontitis associated with systemic diseases, for exam-
ple, human immunodeficiency virus [44]. Reports show that many antimicrobial 
classes are utilized by dentists [37, 45-50]. For empiric therapy, that is, the proper 
selection of which antibiotic to prescribe for patients, the dentists should consider the 
pharmacological characteristic of the antibiotic, the patient’s safety, the probable in-
fectious agent, and the cost of the drug. 
Dentists’ antimicrobials prescription attitude seems to be biased toward certain 
classes of antimicrobials, mainly penicillins and metronidazole [45, 47, 51]. Penicil-
lins and metronidazole prescriptions accounted for about 68 and 26% of the total an-
tibiotic prescriptions issued by 10% of the dentists working in England [47]. Metroni-
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dazole prescriptions issued by dentists accounted for 45% of all metronidazole pre-
scriptions in the United Kingdom [52]. It is estimated that the total dentists’ prescrip-
tions contributed to 7–9% of the total prescriptions issued for the community [52, 
53]. On an average, 159 antibiotic courses per year are prescribed by each dentist in 
the United Kingdom [54]. The average number of prescriptions per dentist per week 
ranged from three in the United Kingdom to 4.45 in Canada [45, 54]. The actual con-
tribution of dentists’ prescriptions to the national antimicrobials consumption is not 
clear.  
Antibiotics commonly used in dental practice 
Most oral infections are polymicrobial because of involvement of Gram-positives and 
Gram-negatives of both anaerobes and aerobic bacteria. In the following section, a 
description of the most-prescribed antibiotics in dental practice is given. This is far 
from being a comprehensive reference of these antibiotics, but may serve as a general 
overview of these agents. 
β-Lactam antibiotics 
Although, Sir Alexander Fleming discovered the penicillin in 1928, the mass produc-
tion of this antibiotic actually began from 1939 when a joint effort was made by 
Great Britain, Canada, and the United States to mass produce penicillin for the 
alliance troops. A wide array of penicillins and other β-lactams antibiotics have been 
synthesized by incorporating various side chains into the β-lactam ring. Of all β-
lactams antibiotics, penicillins are the most widely used antimicrobial agents in 
dentistry. The narrow-spectrum penicillinase-sensitive agents, such as penicillin G 
and penicillin V, and the broad-spectrum aminopenicillins, for example, ampicillin 
and amoxicillin, are of primary interest to dental practitioners. Penicillin V, 
phenoxymethylpenicillin, is orally administered and it is active against streptococci 
and most oral anaerobes [33]. Phenoxymethylpenicillin is effective against a majority 
of α-haemolytic streptococci and penicillinase-negative staphylococci. Aerobic 
Gram-positive organisms, including Actinomyces, Eubacterium, and 
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Peptostreptococcus species, are sensitive together with anaerobic Gram-negative 
organisms, such as, Bacteroides, Prevotella, Porphyromonas, Fusobacterium, and 
Veillonella species. The majority of Staphylococcus aureus strains have developed 
resistance to the drug. Phenoxymethylpenicillin is commonly used by dental 
practitioners in the treatment of acute purulent infections, post-extraction infections, 
and salivary gland infections [33, 40].  
The mode of activity of aminopenicillins is similar to that of phenoxymeth-
ylpenicillin, that is, inhibiting cell wall synthesis, but the former is effective against a 
broader spectrum of organisms, including Gram-negative organisms such as 
Haemophilus and Proteus species. The aminopenicillins owe their extended spectrum 
to an increased ability to penetrate the outer membrane of Gram-negative bacteria. 
Ampicillin is sometimes used in the empirical treatment of dento-alveolar infections 
when the antibiotic sensitivity patterns of the causative organisms are unknown [40]. 
Amoxicillin is the drug of choice for prophylaxis of infective endocarditis [42, 55], 
because of its predictable and reliable absorption after oral administration rather than 
its increased spectrum, in patients undergoing dental treatment procedures requiring 
prophylaxis [33, 42]. It is also common to combine some penicillins with β-lactam 
inhibitory substances such as clavulanic acid, sulbactam, or tazobactam. These in-
hibitors block the β-lactamase enzyme produced by the bacteria from functioning and 
increase the ability of the β-lactam antibiotic to work. 
Metronidazole 
Metronidazole was introduced in the mid-1950s by Rhone-Poulenc under the brand 
name Flagyl. It was the first drug of the group that is now called nitroimidazoles. 
Flagyl was first introduced as a drug in the treatment of trichomonas vaginalis, a 
sexually transmitted disease, and it revolutionized the therapy for that condition. In 
1964, a dentist noted that patients with gingivitis treated with Flagyl for trichomonas 
vaginalis were cured and the second major indication was then established. Flagyl 
was also found useful in the treatment of protozoan parasite Giardia lamblia and in 
the treatment of Entamoeba histolytica during the late 1960s and 1970s. In the early 
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1970s, it was found that Flagyl was very active against the obligate anaerobes of 
which the two best-known families are Bacteroides and Clostridia. Flagyl is regarded 
as the gold standard for treating these infections. 
The exquisite anaerobic activity of this drug makes it exceedingly effective 
against anaerobic bacteria. Metronidazole exerts its effect on bacteria by inhibiting 
microbial RNA synthesis. The drug is active against almost all strict anaerobes in-
cluding Bacteroides, Eubacterium, Fusobacterium, and Peptostreptococcus species. 
The drug is indicated in the treatment of acute necrotizing ulcerative gingivitis and 
for moderate to severe odontogenic infections, frequently in combination with 
penicillins [33, 40]. 
Tetracyclines 
Tetracyclines are broad-spectrum bacteriostatic drugs that bind to the 30S ribosomal 
subunit of bacteria, and specifically inhibit the binding of aminoacyl-t-RNA syntheta-
ses to the ribosomal acceptor site, thus inhibiting protein synthesis [40]. Tetracycline, 
doxycycline, and minocycline are the best-known members of this family of antibiot-
ics. In dentistry, tetracyclines are used with some success as adjunctive treatment in 
localized aggressive periodontitis [40]. Tetracyclines have few side effects but are not 
recommended for children or pregnant women because they can discolor developing 
teeth and alter bone growth [56]. Tetracyclines also have nonantibacterial properties 
that include antiinflammatory, immunosuppressive properties, suppression of anti-
body production in lymphocytes, reduction in phagocytic function of polymorphonu-
clear leukocytes, and reduction of leukocyte and neutrophil chemotaxis. It also acts as 
an inhibitor of lipase and collagenase activity, as an enhancer of gingival fibroblast 
cell attachment, and even has antitumor activity [56-58]. 
Macrolides and lincosamides 
The macrolide-lincosamide-streptogramin B class (MLS) antibiotics contain structur-
ally different but functionally similar drugs. Macrolides are bacteriostatic drugs that 
exert their action by interfering with bacterial protein synthesis by binding to the 50S 
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ribosomal subunit; it is thought to bind to the donor site during the translocation step 
[56]. Erythromycin, clarithromycin, and azithromycin are members in this family. 
Macrolides have activity against streptococci, staphylococci, and some oral 
anaerobes [33]. Erythromycin is used instead of penicillins in penicillin-allergic 
patients with an added advantage of being active against β–lactamase producing 
strains [40]. Clindamycin is a lincosamide and is effective against both aerobic and 
anaerobic species of bacteria and has a wider host range than erythromycin. It is a 
potent bactericidal antibiotic that exerts its action by interfering with protein 
synthesis. In dentistry, clindamycin has its main indication in penicillin-allergic 
patients who require antibiotic prophylaxis prior to dental treatments [59].  
1.3  Antibiotic resistance 
Bacterial resistance to antimicrobials can be defined either genotypically, where the 
bacteria carries certain resistance elements, phenotypically, where the bacteria can 
survive and grow above a certain level of antibiotics in the laboratory; or clinically, 
where the bacteria are able to multiply in humans in the presence of drug concentra-
tions during therapy [60]. Bacterial resistance to antimicrobial agents can be either 
natural (inherent, intrinsic) or acquired. 
Natural (inherent, intrinsic) resistance  
In this type of resistance all isolates of a certain bacterial species are not sensitive to 
the antimicrobial in question. This could be because of a lack of certain structures in 
bacteria that serve as the target molecules for the antimicrobial or the lack of meta-
bolic processes essential for the activation of the antimicrobial. In agreement with 
this, bacteria without a cell wall (e.g., the Mycoplasma species) are naturally resistant 
to antimicrobial agents such as β–lactam antibiotics, having activity against the cell 
wall. Another example of natural resistance is in the case of enterococci and cepha-
losporins. There are no penicillin-binding proteins in enterococci that bind these 
drugs with high affinity, and thus enterococci are intrinsically resistant to these 
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agents. Intrinsic resistance attributable to lack of metabolic processes is also noticed 
among oral bacteria. For example, Actinomyces species, Streptococcus species, and 
A. actinomycetemcomitans lack the enzyme nitroreductase necessary to convert 
metronidazole to its active metabolites, and are not affected by the drug at normal 
therapeutic concentrations. Intrinsic resistance because of a missing metabolic 
process is found in aminoglycosides resistance in enterococci in which the facultative 
anaerobic metabolism limits the uptake of aminoglycosides because of the absence of 
an electron-transport chain. 
Acquired resistance 
In contrast to natural resistance, acquired resistance is found only in some isolates of 
a certain bacterial species. However, sometimes the percentage of resistant isolates 
could reach high figures and susceptible isolates are hardly found. Acquired resis-
tance in bacteria is evolved because of genetic alteration that can be achieved by two 
mechanisms: chromosomal mutation in the preexisting bacterial genome or, most fre-
quently, by horizontal gene transfer between bacteria both within and outside species. 
Horizontal gene transfer allows bacterial population to develop antibiotic resistance at 
a rate significantly greater than would be afforded by mutation of chromosomal 
DNA. Indeed, horizontal gene transfer is the most frequent pathway for the 
dissemination of antibiotic resistance genes. 
For the dissemination of antibiotic resistance gene or genes by horizontal gene 
transfer, a resistance gene may be inserted into transferable genetic elements 
(plasmids, transposons, and integrons) and may be linked within them to other resis-
tance genes. The movement and introduction of transposons, integrons, or plasmids 
(each may carry antibiotic resistance gene or genes), into a bacterium occur via three 
mechanisms, namely, transformation, transduction, and conjugation. In 
transformation, free exogenous segments of DNA carrying resistance genes are ac-
quired by the bacteria from their environment, and the bacteria is required to undergo 
a physiological state termed competence – altered bacterial phenotype by which bac-
teria are able to take up and integrate exogenous free DNA from their environment. 
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Natural transformation was first demonstrated in streptococcus pneumonia in 1928 
by Griffith [61]. Transformation occurs in bacterial species that are naturally 
competent, such as pneumococci, haemophilus, and some oral streptococci. In fact, 
transformation is thought to be responsible for the devolvement and appearance of 
mosaic genes and the mosaic structure of Penicillin Binding Proteins (PBP) 
responsible for penicillin resistance in streptococci. Transduction, firstly described 
in 1953, is similar to transformation except that the exogenous bacterial DNA 
carrying resistance determinants is transferred from one bacterium to another by 
insertion in a phage particle. The last mechanism in horizontal gene transfer is 
Conjugation. Edward Tatum and Joshua Lederberg discovered the principle of 
conjugation in 1947 [62]. They mixed two different strains of Escherichia coli and 
discovered the appearance of recombinant types that were different from the two 
strains they had mixed. It was later shown that this phenomenon was a result of direct 
physical contact between the two different strains and this facilitates the transfer of 
plasmid DNA from a donor to a recipient bacterium (Figure 1A). Many conjugative 
plasmids have been shown to present resistance to a variety of antibiotics. Perhaps 
even more insidious is their demonstrated capacity to transfer to a wide range of 
bacteria. Some plasmids are not conjugative, but rather are termed mobilizable [63]. 
Such plasmids can be transferred to a recipient if the conjugative functions are 
provided by a separate self-transmissible plasmid that is also harbored within the 
bacteria (Figure 1B). Mobilizable plasmids have not been as thoroughly studied as 
conjugative plasmids but may be equally responsible for the spread of antibiotic 
resistance genes and development of multidrug-resistant bacteria [63]. 
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Figure 1. (A) Conjugative transfer of plasmid between cells. (B) Transfer of a mobilizable plasmid between 
cells assessed by a conjugative plasmid (adopted from Moritz and Hergenrother, 2007). 
 
 
 
 
 
 
 
 
 
 
 
  
 
B)  Mobilizable plasmids
Donor bacterium
 
Donor bacterium
Recipient bacterium 
Direct cell 
contact 
Plasmid 
ssDNA 
transferred 
dsDNA 
synthesized and 
circularizes 
Both cells have 
the plasmid and 
separate  
Conjugative 
plasmid allows 
cell contact 
Mobilizable 
plasmid ssDNA 
transferred 
dsDNA 
synthesized and 
circularizes 
Both cells have 
the plasmid and 
separate   
  
 
 
  
Recipient bacterium 
A)  Conjugative plasmids
                                                                                  Oral bacterial resistance 
 
21
Transposons and integrons are mobile DNA elements that can insert and be 
integrated into regions of DNA on the chromosome or plasmids of Gram-positive and 
Gram-negative bacteria. Transposons associated with antibiotic resistance fall into 
three major classes based on their general structure and method of insertion. The first 
two classes consist of composite and noncomposite transposons that integrate into 
target DNA by generating direct repeats in the target sequence (Figure 2A) [63]. 
Composite and noncomposite transposons typically contain genes that are not essen-
tial for their transposition (such as antibiotic resistance determinants) in between 
flanking terminal insertion sequences (composite) or inverted repeats 
(noncomposite). Because transposition can involve excision and transfer of the entire 
element, such transposons are important in the spread of antibiotic resistance genes 
[63]. The third class, defined as conjugative transposons, are capable of excision from 
the chromosome or a plasmid of the donor cell to transfer DNA via conjugation into a 
recipient bacterium (Figure 2B). Conjugative transposons have a broad host range 
and their transfer is not constrained to closely related bacteria; this has been 
demonstrated by the Tn916 and Tn1545 family of transposons, which have been 
found or introduced into 50 different species and 24 genera of bacteria encompassing 
both Gram-negatives and Gram-positives [63]. Conjugation of a conjugative 
transposon begins with the excision of the transposon from either the bacterial 
chromosome or plasmid DNA. The transposon DNA becomes circular and 
conjugative transfer of a single-stranded DNA copy to the recipient cell proceeds in a 
manner identical to plasmid conjugation. A wide variety of antibiotic resistance genes 
have been discovered on large conjugative transposons, and they are thought to be a 
significant contributor to the spread and increase of antibiotic resistance in Gram-
positive bacteria. The last type of mobile genetic elements is the integrons. These 
mobile genetic elements consist of an integrase gene, two promoters transcribing in 
opposite direction, and an array of other genes, which often contain antibiotic 
resistance genes (Figure 2C) [63]. Integrons differ from transposons in that the 
former possess a site-specific recombination system and do not randomly excise or 
insert into DNA regions. Importantly, many antibiotic resistance genes have been 
found as part of integrons and such gene cassettes are capable of insertion and 
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excision from other mobile genetic elements or the bacterial chromosome. Thus, 
resistance determinants present on some transposons and plasmids may be the result 
of integron insertion [63]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.(A) Integration of a transposon into a target DNA (transposition); IS, insertion sequance. (B) 
Excision, circulation and subsequent conjugative transfer by a conjugative transposon into a recipient cell. (C) 
Acquisition of an array of genes by an integron via sitespecific recombination (adopted from Moritz and 
Hergenrother, 2007). 
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Mechanisms of antibiotic resistance  
Specialized defence mechanisms, encoded by the acquired resistant genes, are 
utilized by bacteria for their survival in an environment in which antimicrobials are 
designed to kill them. Generally, one or more of four principal ways are utilized by 
bacteria to render antimicrobials ineffective (Figure 3) [60]. These are the following: 
 (1) The target molecules are structurally altered to prevent antibiotic binding. An ex-
ample of this includes the alteration of ribosomal target sites in the DNA 
gyrase/topisomerase genes that are the targets of fluoroquinolones. Modification of 
the PBPs may occur through mutation in the chromosomal genes encoding the en-
zymes or through the acquisition of foreign homologous genes or fragments of genes 
from related species encoding new PBPs, a mechanism which is prevalent in Gram-
positive cocci but seen less frequently in Gram-negative bacteria. Methicillin-
resistant S. aureus (MRSA) is known to produce an alternative PBP (2a) that 
bypasses the effect of the antibiotic. Resistance to β-lactam antibiotics might be 
caused by the production of low-affinity PBPs. This resistance mechanism is 
widespread among the oral viridans streptococci, such as, Streptococcus oralis, 
Streptococcus sanguis, and Streptococcus mitis.  
(2) Antibiotics are excluded from cell entry. Several antibiotics utilize porin channels 
when entering Gram-negative bacteria. So, the decreased expression of porins results 
in impermeability or decreased uptake that often leads to antibiotic resistance.  
(3) Antibiotics are pumped out of the cell through a mechanism known as efflux 
pump. The bacteria can actively efflux the antimicrobial agent. Five major families of 
the efflux system are present. These are MFS: Major Facilitator Superfamily; RND: 
Resistance Nodulation-Division; SMR: Small Multidrug Resistance; ABC:  ATP-
Binding Cassette; and MATE: Multidrug and Toxic Extrusion. 
(4) Antibiotics are inactivated, for example, through enzymatic degradation. The 
most common example of this mechanism is resistance against β-lactam antibiotics 
because of β-lactamases. These enzymes present resistance to the most widely used 
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antimicrobials in medical and dental practice, that is, β–lactams. Therefore, a special 
account, with some detailed information, for these enzymes is given.  
 
 
Figure 3. Resistance mechanisms of bacteria (reproduced with permission from Dr. Grace Yim). 
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Table 1. summarizes the mechanisms of action, antimicrobial spectra and main 
antimicrobial resistance mechanisms of the main antimicrobials used in dentistry. 
 
Table 1. Main antibiotics used in dentistry, mechanism of action, their spectrum, and main bacterial resistance 
mechanisms involved. 
Drug Mechanism of action Spectrum Main resistance mechanism(s) 
Phenoxymethyl-
penicillin 
inhibition of cell wall 
synthesis 
aerobic G+, 
anaerobic G+, 
anaerobic G –
(narrow-spectrum) 
enzymatic (β-lactamases), 
alteration of the target site 
(mosaic PBP) [64, 65] 
 
Amoxicillin, 
Ampicillin 
inhibition of cell wall 
synthesis 
 
as above plus 
haemoghilus spp. 
(broad-spectrum) 
as above 
Metronidazole inhibition of RNA 
synthesis 
strict anaerobic 
bacteria, some 
facultative anaerobes 
enzymatic (5- nitroimidazole 
reductase) [66] 
Erythromycin inhibition of protein 
synthesis 
mainly G + target site modification, 
enzymatic inactivation, and 
active efflux [67, 68]  
Clindamycin inhibition of protein 
synthesis 
as above plus 
additional activity on 
anaerobes 
as above 
Tetracycline inhibition of protein 
synthesis 
many G + and  G – active efflux, enzymatic 
inactivation, ribosomal 
protection proteins [69, 70] 
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β-Lactamases 
More than 300 β-lactamases from various bacteria differing in substrate profiles, po-
tential for inhibition, and physiological characteristics, have been described. These 
enzymes catalyze the hydrolysis of the β-lactam ring of the β-lactam antibiotics, re-
sulting in microbiologically inactive compounds. Several classification schemes for 
β-lactamases have been proposed [71-74]. The molecular classification scheme is the 
simplest and it is comprised of four distinct molecular classes (A,B,C, and D) based 
on amino acid sequences [74]. Classes A, C, and D comprise evolutionarily distinct 
groups of serine enzymes, and class B contains the zinc types. The most threatening 
of these enzymes are the metallo-β-lactamases; molecular class B β-lactamases, that 
inactivate almost all β-lactam drugs, even the carbapenem antibiotics [64, 72]. Addi-
tionally, extended spectrum β-lactamases (ESPLs) have evolved from mutations 
around the active site of the parental β-lactamases (class A and D) and extending their 
substrate spectrum to hydrolyze a panel of β-lactam antibiotics [64, 75]. The genes 
encoding for the production of β-lactamase could be chromosomal or inserted on a 
mobile genetic element, for example, plasmid, that travel from one bacterium to an-
other [64]. 
 The β-lactamases production by bacteria could be copious, whether constitu-
tively or inducibly [64, 73]. The β-lactamases of Gram-positive bacteria are generally 
excreted in large amounts and may therefore, in mixed infection, also protect other 
organisms present at the infection site. This could be of particular clinical importance 
in biofilm-associated diseases. The permeability characteristics may act in concert 
with β-lactamase production to protect the microorganism from the effects of β-lac-
tam antibiotics. Therefore, decreased permeability of the antibacterial agent allows 
small amounts of strategically located β-lactamase to present high resistance [76]. 
Previous studies shown a high penicillins susceptibility (90–99%) of oral bac-
teria recovered from subgingival plaque samples [77, 78]. It was in the 1980s when 
reports began to emerge and information about clinical failure of penicillin therapy in 
the treatment of oro-facial infections from which penicillin-resistant and β-lactamase 
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producing oral Bacteroides, Capnocytophaga, Veillonella, and Streptococcus strains 
were isolated [23, 79, 80]. In addition, β-lactamase producing Bacillus and 
Pseudomonas species were isolated from subgingival plaque in patients with chronic 
periodontitis [81]. The Prevotella species have been reported to be the most frequent 
β-lactamase producing species found in the periodontal pockets and saliva [35, 81, 
82]. The β-lactamase producing Prevotella species were frequently found to colonize 
infants and healthy young children [35, 83]. Isolates of F. nucleatum have earlier 
been shown to produce significant amounts of β-lactamase in patients suffering from 
tonsillitis [36]. In addition, Könönen et al. demonstrated that penicillin resistance 
caused by β-lactamase production by oral strains of F. nucleatum frequently occurs in 
childhood [84]. The susceptibility of P. gingivalis isolates to penicillins have been 
reported to be 100% and it was thought that the bacterium has no β-lactamase 
enzymes [82, 85-87]. However, Nagy et al. investigated 183 clinical isolates of 
Bacteroides, Porphyromonas, and Prevotella species, from severe infections after 
abdominal, gynaecological, and oral surgery, to detect β-lactamase production and β-
lactamase producing Porphyromonas; P. gingivalis were detected mainly in 47% of 
the isolated strains [88]. In addition, Prieto-Prieto et al. referred to a study conducted 
in Spain in which 59% of Porphyromonas species were resistant to penicillin G [89]. 
Molecular characterization of β-lactamases produced by oral bacteria was 
started in 1991 by Lacroix et al. in which a β-lactamase gene (TEM-1) in an E. 
corrodens strain, isolated from the periodontal pocket, was sequenced [90, 91]. More 
studies were then published on the characterization of β-lactamases produced by oral 
bacteria, mainly in Bacteroidaceae, as members of this family had been implicated in 
the etiology of acute oral infections and periodontal disease [92, 93]. More recently, 
detection and characterization of a panel of β-lactamase genes produced by different 
subgingival oral bacteria isolated from patients with refractory periodontitis, currently 
known as recurrent periodontitis, were reported and in this study the CfxA β-lac-
tamase gene was found to be prevalent in Prevotella and Capnocytophaga species 
[94, 95].  
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Use of antibiotics and development of resistance 
“Antibiotic therapy, if indiscriminately used, may turn out to be a medicinal flood that tem-
porarily cleans and heals, but ultimately destroys life itself” Felix Marti-Ibanez, 1955. 
Resistance development is a natural biological outcome of antibiotic use [96]. It 
represents a particular aspect of the general evolution of bacteria that is genetically 
determined and presents a survival advantage. The selection pressure applied on bac-
terial population when antimicrobials are used is the driving force for the resistant 
bacteria to emerge [96-98]. Therefore, resistant bacterial clones have been continu-
ously selected as an evolutionary response to the use of antibiotics. The magnitude of 
this selection is determined by the total consumption of antibiotics within the par-
ticular setting in which these antibiotics are used. Indeed, the correlation between the 
antibiotic use and emergence of bacterial resistance is well established and is clearly 
seen by the frequency of resistant bacteria that is considerably higher in countries 
with high antibiotic consumption [99]. However, a quantitative relation between the 
two factors, that is, antibiotic use and bacterial resistance, was not clear. 
The development of resistance appears to follow a sigmoid distribution, with a 
lag phase before resistance appears, then a relatively rapid increase in the proportion 
of resistant bacteria, followed by a third phase in which the proportion between sus-
ceptible and resistant bacteria reaches an equilibrium [100]. This equilibrium level is 
determined by the relative fitness of resistant and sensitive strains including transmis-
sion ability, the genetic basis and stability of resistance, and the magnitude of the an-
tibiotic selection pressure. When this level of resistance has been reached, measures 
to contain or potentially lower the resistance level seem very difficult [101]. One 
strategy that has been widely adopted to curtail the rapid emergence and subsequent 
dissemination of resistance genes is to restrain the use of antibacterial drugs [102-
104]. Despite the fact that many countries adopt antibiotic treatment guidelines, re-
striction of antibiotic use outside human medicine, and improved diagnostic tools for 
bacterial infections, the global trend of antibiotic resistance is still on the increase. 
Globally there is an extensive overuse of antibiotics, for example, use based on incor-
rect medical indications as well as misuse by using the wrong agent, administration 
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route, dose and treatment duration [105, 106]. In industrialized countries, around 80–
90% of antibiotic consumption in humans takes place in the community, and at least 
half of this is considered to be based on incorrect indications, mostly viral infections 
[106-108]. Easy access to antimicrobial agents in several countries is a big problem 
as well. There are also nonclinical factors that influence the use of antibiotics. Those 
include cultural conceptions, patient demands, economic incentives, and advertising 
to prescribers, consumers, and providers from the pharmaceutical industry [109, 110]. 
Consequently, the patterns of antibiotic use differ substantially between and within 
countries [99]. In Europe, for example, antibiotic consumption is four times higher in 
France than in the Netherlands, although there is no reason to believe that the burden 
of disease differs between the two countries [99]. 
 In developing countries, a high infectious disease burden commonly coexists 
with high antibiotic consumption and rapid emergence and spread of microbial resis-
tance [111, 112]. Several risk factors for resistance emergence particularly pertinent 
to, but not limited to, developing countries exist [111, 112]. Among these are misuse 
and easy access of antibiotics, poor quality antimicrobials, and lack of patient compli-
ance to the prescribed drug and regimen. In addition, dissemination of resistant bacte-
ria in developing countries is facilitated by inadequate infection control measures in 
health facilities and shortfalls in hygiene, sanitation, and public health [111, 113]. 
The potential reversibility of resistance is a debatable issue, and the chances of 
success differ greatly between the hospital setting and the community. The rationale 
for reversibility is that resistant bacteria will have a disadvantage over susceptible 
strains in environments without antibiotics, as most resistance mechanisms will pre-
sent a reduction in bacterial fitness, for example, a slower growth rate, reduced viru-
lence or transmission rate [114-116]. Thus, a decreased volume of antibiotic use 
should lead to lower selection pressure and a reduction in the proportion of bacteria 
resistant to a certain antibiotic. In line with this, Feres et al. found that the prevalence 
of amoxicillin-resistant subgingival bacteria that emerged with a 14-day amoxicillin 
therapy decreased from 37% to the baseline value (0.5%) in a 90-day period [117]. 
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Thereby, resistant organisms are replaced by susceptible ones as a consequence of 
removal of the selective-pressure-driving force, that is, antibiotics. However, the 
issue of reversibility is complicated by the fact that resistant bacteria may reduce the 
biological costs associated with resistance through compensatory evolution [118, 
119], therefore, reversibility is difficult to achieve in highly adapted resistant strains. 
It is expected that reversibility would be higher in communities than in hospital 
settings, especially as the continuous antibiotics use in hospitals would allow better 
adaptability to reduce the biological costs associated with resistance. However, it was 
noticed that in hospital settings the rate and extent of reversibility of antibiotic 
resistance among isolates are much higher than in communities. The reason for this 
difference is that the main driving force for reversibility in hospitals, in contrast to 
communities, is not the biological cost of resistance. Instead, in hospitals a “dilution 
effect” is observed as patients admitted from the community in most cases bring 
susceptible bacteria into clinical wards and therefore affect the levels of resistant 
bacteria [120].  
It is generally agreed that more the antimicrobials used, the more is the selec-
tion pressure applied on bacterial population, and resistant bacteria began to emerge. 
Therefore, detailed and extensive information on antibiotic utilization has gained in-
terest in many communities, and the antibiotic consumption measurement is increas-
ingly being recognized as an important factor of monitoring emerging resistance. 
Measuring antibiotic consumption 
The pioneering work of Arthur Engel in Sweden and Pieter Siderius in Holland 
alerted many investigators to the importance of comparing drug use between different 
countries and regions [121]. However, in the early work, drug utilization data ob-
tained from different countries did not permit detailed comparisons because the 
source and form of the information varied between them. To overcome this difficulty, 
researchers in Northern Ireland, Norway, and Sweden developed a new unit of meas-
urement, initially called the agreed daily dose [122] and later the Defined Daily Dose 
(DDD) [123]. The DDD unit is defined as the average maintenance dose of the drug 
                                                                                  Oral bacterial resistance 
 
31
when used for its major indication in adults. Another important methodological ad-
vance was the development of the uniform Anatomical Therapeutic Chemical (ATC) 
classification of drugs by Norwegian researchers. In the ATC classification, drugs are 
classified in groups at five different levels. The drugs are divided into 14 main groups 
(first level); the second level in the ATC classification system is the therapeutic 
group. The third and fourth levels are the chemical/pharmacological/therapeutic sub-
groups. The fifth level is the chemical substance. The complete classification of 
amoxicillin illustrates the ATC classification system (Table 2).  
The “DDD/ATC system” is adopted by WHO and researchers are advised to 
use this standardized methodology that allows meaningful comparisons of drug use in 
a country or between different countries to be made. The WHO Collaborating Centre 
for Drug Statistics Methodology, located at the Norwegian Institute of Public Health, 
Department of Pharmacoepidemiology, Oslo, is responsible for the development and 
maintenance of the “ATC/DDD system” [124].  
Antibiotic consumption measurements can describe the extent of use at a cer-
tain moment and/or in a certain area (e.g. in a country, region, community or hospi-
tal). It could be presented as numbers of DDDs per 1000 inhabitants per day or, when 
antibiotics use by inpatients is considered, as DDDs per 1000 bed-days [125]. The 
number of DDDs/1000 inhabitants/day gives an estimate of the proportion of the 
population exposed daily to a particular drug. This figure is a rough estimate and 
should be read with caution.  
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Table 2. Description of ATC classification system (amoxicillin is used as an example)  
Description of ATC classification ATC classification System corresponding to ATC classification 
1st level, anatomical main group 
2nd level, therapeutic group 
3rd level, chemical subgroup 
4th level, therapeutic subgroup 
5th level, chemical substance 
J 
J01 
J01C 
J01CA 
J01CA04 
Anti-infective for systemic use 
Antibacterial for systemic use 
Beta-lactam antibacterial, penicillins 
Penicillins with extended spectrum 
Amoxicillin 
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2. Rationale and aims of the study 
The work in this thesis was prompted by the very liberal use of antibiotics in many 
developing countries compared to some developed countries and the international 
concern regarding increasing antibiotic resistance of oral bacteria. The author hy-
pothesized that Yemen is one of these antibiotic-misusing developing countries and, 
therefore, decided to investigate the situation in his homeland, Yemen, and compare 
it with that in a developed country, Norway. The general aim of the current study was 
to investigate antibiotic resistance in oral bacteria in both Yemen and Norway. The 
specific objectives were: 
 
(1)  To assess and compare the prevalence of selected subgingival bacteria resis-
tant to aminopenicillins and metronidazole, in Yemen and Norway (paper 1). 
(2)  To assess the susceptibility pattern of F. nucleatum species isolated from 
Yemen, and to characterize its aminopenicillins-resistant determinants (paper 2). 
(3) To elucidate antimicrobials prescription practices among dentists in Yemen 
(paper 3) and Norway (paper 4), and the possible contribution of these practices 
to the emergence of bacterial resistance.  
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3. Material and Methods 
3.1 Study subjects and study data (papers 1, 2, 3, and 4)  
A total of 55 patients were enrolled as plaque donors of whom 34 and 21 were from 
Yemen and Norway, respectively (paper 1). Another 23 plaque donors from Yemen 
were enrolled in paper 2. All plaque donors were dental-clinic attendees for various 
treatment demands, and were asked for verbal consent prior to sampling; Plaque col-
lection was approved by the Regional Ethical Committee for Medical Research, 
West-Norway. None of them had any antimicrobial therapy in the previous three 
months. In paper 3, a questionnaire comprised of 65 close-ended questions that 
sought answers to 11 parameters were distributed by hand (the author) to 280 dentists 
working in all the governmental as well as private dental clinics in the three major 
governorates (Sana’a, Aden, and Taiz) in Yemen. The questionnaire investigated 
demographic data of the dentists and their knowledge on therapeutic and prophylactic 
antimicrobial usage in clinical dentistry. Aggregated data on antibiotic prescriptions 
by dentists in Norway were analyzed (paper 4). The data were obtained from the 
Norwegian Prescription Database (NorPD) and it contained the numbers of 
prescriptions issued by dentists, the number of dentists having prescribed the 
antibiotics, and the total DDDs in 2004 and 2005 of 11 antibiotics 
(phenoxymethylpenicillin, amoxicillin, erythromycin, doxycycline, metronidazole, 
clindamycin, tetracycline, spiramycin, oxytetracyclin, clarithromycin, and 
azithromycin) used in dentistry.  
   
3.2 Plaque sampling and primary cultures (papers 1 and 2) 
After clinical examination and removal of supragingival plaque, three randomly se-
lected posterior teeth in each patient were assigned for isolation and subgingival sam-
pling. The subgingival samples were collected using sterile paper points size 50 
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(Dentsply, USA) that were inserted as far as possible subgingivally parallel to the 
long axes of the sampled teeth and removed after 20 s. The three samples thus ob-
tained from each subject were placed in a sterile vial containing 1.5 mL VMGA ΙΙΙ 
transport medium [126]. All samples were transported to the Laboratory of Oral Mi-
crobiology, University of Bergen, within 48 h after sampling at ambient temperature 
in plastic bags under anaerobic condition using the Anaerocult® system (Merck). 
Upon arrival at the laboratory, 3–5 sterile glass beads were added aseptically to each 
vial. The samples were then vortexed (WhirliMixer, Fisons Scientific Equipment, 
England) for 2 min. Thereafter, 10 µL of each sample suspension were plated on fas-
tidious anaerobic blood agar (Lab M, UK) or crystal violet erythromycin (CVE) 
plates [32] with or without either 2 µg/mL ampicillin or 2 µg/mL metronidazole. The 
inoculated plates were incubated anaerobically (5% CO2, 10% H2 and 85% N2) for 10 
days at 37°C using the Anoxomat System™ (MART Microbiology BV, The 
Netherlands). 
3.3 Bacterial strains (Papers 1 and 2) 
Paper 1 investigated the presence of 18 selected subgingival bacteria resistant to am-
picillin and metronidazole in dental plaque samples from Yemen and Norway. The 
list of the bacterial strains used for the preparation of whole genomic DNA probes, 
used for detection of studied strains, is listed in Table 3. Paper 2 screened F. 
nucleatum isolates from Yemen (n=23) for ampicillin minimum inhibitory concentra-
tions (MICs) and then the assessment for β-lactamase production of resistant strains 
was done. Five highly ampicillin-resistant (MIC > 8 µg/mL) and four susceptible F. 
nucleatum isolates were used for proteomic analysis. In the E-test, Eggerthella lenta 
ATCC 43055 and Bacteroides fragilis ATCC 25285 reference strains were used for 
quality control strains. The E. coli ATCC 25922 strain was used as a negative control 
in the β-lactamase production test. In addition, a β-lactamase positive clinical strain 
of F. nucleatum [35] was used as a positive control in the chromogenic cephalosporin 
disk (Fluka, Germany) test for β-lactamase production. 
         Mohammed Al-Haroni                                                                                      
 
36
 
 
Table 3. Bacterial strains used in papers 1 and 2. 
Species Strain Species Strain 
Porphyromonas gingivalis *  
Prevotella intermedia * 
Aggregatibacter  
actinomycetemcomitans * 
Eikenella corrodens  * 
Camphylobacter rectus  * 
Capnocytophaga gingivalis  *  
Fusobacterium nucleatum  * 
Peptostreptococcus micros  * 
Streptococcus mutans  * 
Streptococcus oralis  * 
ATCC 33277 
VPI 4197 
ATCC 33384 
 
ATCC 23834 
ATCC 33238 
ATCC 33624 
ATCC 23736  
CCUG 17638 
ATCC 25175 
ATCC 10557 
Streptococcus sanguinis  * 
Streptococcus constellatus  * 
Streptococcus gordonii  * 
Streptococcus mitis  * 
Streptococcus intermedius  * 
Tanerella forsythensis  *  
Veillonella parvula  * 
Eubacterium nodatum  * 
Eggerthella lenta # 
Bacteroides  fragilis # 
Escherichia  coli #  
ATCC 10556 
ATCC 27823 
CCUG 33482 
ATCC 9811 
ATCC 27335 
FDC 2008 
ATCC 10790 
CCUG 15996 
ATCC 43055 
ATCC 25285 
ATCC 25922 
* Bacterial strains used for preparation of whole genomic DNA probe [127]                                                                            
# Bacterial strains used for the E-test and β-lactamase production test                                                                             
ATCC: American Type Culture Collection, USA; VPI: Virginia Polytechnic Institute and State University, 
USA; CCUG: Culture Collection, University of Gothenburg, Sweden; FDC: Forsyth Dental Center, Boston, 
USA. 
3.4 Identification of studied species 
DNA-DNA hybridization (paper 1) 
Standardized bacterial sample suspensions were prepared for DNA-DNA checker-
board hybridization technique [10] for detection of the presence and identification of 
the studied species in the cultivated plaque samples. Hybrids were detected by 
chemiluminescence, and then they were exposed to X-ray films (Roche Diagnostic, 
Basel, Switzerland) to detect bound probes. Inspection of hybirds was done visually 
on digitized images of the X-ray films at least for three times on different occasions. 
Hybrids were interpreted according to standard signals (controls 105 and 106 cells) of 
the 18 studied species.  
Phenotypic tests and biochemical assays (paper 2)  
                                                                                  Oral bacterial resistance 
 
37
Fusobacterium nucleatum isolates were recovered from plaque samples on the CVE 
plates [32]. Subsequent identification was based on stereomicroscopic colony mor-
phology, Gram staining, anaerobosis, and a biochemical profile of 29 miniaturized 
enzymatic tests using the commercial assay Rapid ID 32 A system (Biomerieux® Sa, 
France). 
3.5 Antimicrobial susceptibility testing  
Agar dilution method (paper 1) 
Direct plating of 10 µL of bacterial sample suspensions on fastidious anaerobic blood 
agar (Lab M, UK) plates supplemented with either 2 µg/mL ampicillin or 2 µg/mL 
metronidazole were used for testing the presence of resistant species [117].  
The Epsilometer test (E-test) (paper 2) 
Determination of the MICs of the isolated F. nucleatum strains were performed using 
the E-test (AB Biodisk, Sweden) on brucella agar plates (SBA; BBL), 5% sheep 
blood, supplemented with 1 µg/mL vitamin K, and 5 µg/mL hemin. Resistant isolates 
were then screened for β-lactamase production using the chromogenic cephalosporin 
disk test (Fluka, Germany) for β-lactamase production. 
3.6 Proteomics (paper 2) 
Sample preparation  
Ampicillin-resistant and susceptible F. nucleatum isolates were cultured on fastidious 
anaerobic blood agar plates (Lab M, UK) and incubated anaerobically (5% CO2, 10% 
H2 and 85% N2) using the Anoxomat System™ for 48 h at 37°C. The colonies of 
each F. nucleatum isolate were removed from the agar surface using a disposable 
sterile plastic loop and suspended in PBS-A buffer for washing. Extraction of soluble 
proteins of F. nucleatum isolates were performed using a hand-held homogenizer in a 
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buffer containing 7 M deionized urea, 2 M thiourea, 4% (w/v) 3-[3-(cholamidopro-
pyl)-dimethylammonio]-1-propane sulphonate (CHAPS), 0.3%  (w/v) dithiothreitol 
(DTT), and 0.2% carrier ampholyte (Bio-Lyte® 3/10 and/or 5/8 Ampholytes). Deter-
mination of protein concentration of the samples was based on the Lowry methods 
using (Bio-Rad RC-DC™ protein assay).  
Two dimensional gel electrophoresis and protein identification by peptide mass 
mapping and MALDI-TOF/TOF MS 
The isoelectric focusing (IEF) of the samples (first dimension separation) was per-
formed on immobilized pH gradient (IPG) gel strips (7 cm length and ranges pH 3–
10 and 5–8 linear gradient; Bio-Rad Ltd) using the PROTEAN IEF Cell (Bio-Rad). 
The second dimension electrophoresis was performed on sodium dodecyl sulfate 
(SDS) polyacrylamide gels (12% precast SDS-PAGE gels; Bio-Rad) using the Mini 
Protean II gel system (Bio-Rad). Localization of protein on gels was done using Bio-
safe coomassie blue stain (Bio-Rad). LabScan (GE Healthcare) and ImageMaster 2D 
Platinum software version 5 (GE Healthcare) were used for image acquisition and 
subsequent analysis of digitized images. 
 Acquisition of the peptide mass spectra for protein identification was done on 
an Ultraflex Matrix Assessed Laser Desorption Ionization- Time of Flight/Time of 
Flight Mass Spectrometer (MALDI-ToF/ToF MS; BRUKER Daltonic GmbH, Ger-
many). The acquired mass spectra of peptides were used to search in the NCBInr, 
MSDB and Swissprot protein databases using the Mascot search engine 
(http://www.matrixscience.com/).  
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4. Results 
Paper 1 
In both Yemeni and Norwegian subgingival plaque samples, all the 18 studied 
species (Table 2) were detected but at different frequencies. Significant differences 
were found in species prevalence in the two study population. P. gingivalis, 
Eubacterium nodatum, Streptococcus sanguinis, and Veillonella parvula were 
significantly more prevalent in the Yemeni subjects (P < 0.05). On the other hand, A. 
actinomycetemcomitans, Capnocytophaga gingivalis, and S. mitis showed a signifi-
cantly higher prevalence in the Norwegian samples. 
 In the samples from the Yemeni subjects, 28.9 and 60.3% of all detected spe-
cies were resistant to ampicillin and metronidazole, respectively. The corresponding 
figures for the Norwegian samples were 7.9 and 11.3%. Yemeni samples exhibited a 
significantly higher prevalence of metronidazole resistance among Eikenella 
corrodens, Streptococcus mutans, S. oralis, S. sanguinis, Streptococcus constellatus, 
Streptococcus gordonii, S. mitis, Streptococcus intermedius, and V. parvula as well as 
a significantly increased prevalence 
of ampicillin-resistant P. gingivalis, Prevotella intermedia, S. constellatus, S. 
intermedius, T. forsythensis, F. nucleatum, and V. parvula.  
Paper 2 
The ampicillin MICs of F. nucleatum isolates ranged between 0.125 and 256 µg/mL. 
All the ampicillin-resistant F. nucleatum isolates turned the nitrocefin-impregnated 
discs into red indicating hydrolysis because of β-lactamase production. The analysis 
of the ampicillin-resistant F. nucleatum global gene expression at the level of the 
proteome revealed the presence of a 29 KDa protein. This protein was identified 
using Mascot search of the obtained peptide mass fingerprint spectra as class D β-lac-
tamase. There was increased synthesis of two proteins at 37 and 46 KDa that were 
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significantly associated with ampicillin-resistant F. nucleatum isolates. These 
proteins were identified using the Mascot search of the obtained peptide mass 
fingerprint spectra as ABC transporter ATP-binding protein and enolase, 
respectively. 
Paper 3 
A total of 150 properly completed questionnaires by Yemeni dentists were analyzed 
and knowledge scores were calculated. Yemeni dentists’ knowledge of conditions for 
prescribing antimicrobials in the various parts of the questionnaire was generally poor 
(mean score 28.5, s.d. 5.6). The patients’ clinical conditions, dental treatment proce-
dures, and the medical background of the patients were the parameters that scored 
poorest, with a high tendency of overprescribing antibiotics, as compared to current 
international recommendations. The data showed that penicillins, mostly broad-spec-
trum, were the first choice of antibiotics (72%) followed by spiramycin (10%) when 
treating dental infections. No statistically significant difference was found among age 
band groups. Significant difference in scores was found (p<0.001) between genders 
with lower female mean score than male mean score (27.6, s.d. 4.6 and 29.57, s.d. 
5.9, respectively). 
Paper 4 
A total of 268,834 prescriptions issued by 4765 different dentists working in all types 
of dental settings in Norway in both 2004 and 2005 were analyzed. The narrow-spec-
trum-penicillin phenoxymethylpenicillin was the most frequently prescribed 
antibiotic by dentists in Norway followed by metronidazole. 
Phenoxymethylpenicillin and metronidazole prescriptions accounted for 75 and 6.3% 
in 2004, respectively, versus 73 and 6.9% in 2005 of all the dentists’ antibiotic 
prescriptions. The prescription frequencies of the 11 antibiotics prescribed by dentists 
in Norway are presented in Table 4. The average number of prescriptions per dentist 
per week during the study period was 0.59. The broad-spectrum amoxicillin 
accounted for approximately 4.6% of all the prescriptions issued in 2004 and 2005. 
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Dentists’ antibiotic prescriptions in Norway contributed to about 8% to the total 
consumption of the 11 drugs. 
 
Table 4. The prescription frequencies of the 11 antibiotics prescribed by dentist in Norway in 2004 and 2005 
Dentists’ prescriptions Dentists’ prescriptions Prescribed antibiotics 
2004 2005 
Prescribed antibiotics 
2004 2005 
Phenoxymethyl-
penicillin 
Metronidazole 
Erythromycin 
Amoxicillin 
Clindamycin 
Doxycycline 
          
75% 
6.3% 
4.9% 
4.6% 
3.7% 
2.3% 
          
73% 
6.9% 
5% 
4.7% 
4.4% 
2.2% 
              
Azithromycin 
Spiramycin 
Tetracycline 
Oxytetracyclin 
Clarithromycin 
       
1.2% 
0.7% 
0.7% 
0.2% 
0.08% 
              
1.1% 
0.6% 
0.5% 
0.2% 
0.00% 
 
 
 
 
 
 
 
 
         Mohammed Al-Haroni                                                                                      
 
42
5. Discussion 
The present study investigated, for the first time, antibiotic resistance among selected 
oral bacteria in Yemen and compared the findings from Yemen and Norway. The 
main findings were the high prevalence of antibiotic resistance among isolates from 
Yemen, thus confirming my hypothesis of antibiotic misuse, and the association with 
poor knowledge of antibiotic prescription among Yemeni dentists. It was shown that 
aminopenicillin resistance among F. nucleatum isolates from Yemen was mainly be-
cause of class D β-lactamase production. In addition, dentists’ contribution to the na-
tional consumption of antibiotics in Norway was measured, also for the first time, 
using the WHO DDD/ATC system. The results indicate that the prescription practices 
among dentists in Norway are conservative.  
5.1 General discussion 
Antibiotics and other antimicrobial drugs have revolutionized the treatment of infec-
tious diseases since their introduction in the beginning of the last century. In 1945, 
Sir Alexander Fleming, during his Nobel Prize acceptance speech for his penicillin 
discovery in 1928, warned the scientific community about the danger of antibiotic 
resistance that microbes can develop, and he informed that it is not difficult to make 
microbes resistant to penicillin in the laboratory by exposing them to nonlethal 
quantities of penicillin. The use of different antibiotics for many years led to the 
emergence of infectious bacteria that are resistant not only to one but to several 
antibiotics. As a result, there are strains of bacteria today for which only one effective 
drug treatment is available or, in some cases, none at all [128]. Antimicrobial 
resistance by microbes is now considered as a major threat to public health and its 
control is now an international priority for action.     
Nowadays, the world is considered smaller than before as a result of better 
communications. The public health issues are increasingly regarded and seen as one 
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global issue that affect all countries. Unfortunately, in many parts of the globe there 
are still some countries that are bounded by so many restrains, making them less de-
veloped. Many major global health problems continue to present a dilemma in these 
countries.  
Antibiotic resistance in oral microbes is an increasing problem when treating 
dental infection. In the recent years, a shift from narrow-spectrum antibiotic prescrip-
tions to broad-spectrum ones by dentist was reported, and the increase of bacterial 
isolates resistant to the former antibiotics is blamed for such a shift in prescription 
practices. On the other hand, the issue of antibiotic resistance is neglected in Yemen, 
and scientific studies that deal with this topic are lacking. Therefore, there was a 
strong motive for the author to conduct this work. The author tried to measure antibi-
otic resistance among some selected oral microbes in Yemen to compare it to that in 
Norway in a reliable way and from different aspects. Norway is a country that pos-
sesses several characteristics to be an ideal model for comparison. It is aimed to be 
the initial step to appreciate how big the problem is in Yemen and to improve the na-
tion’s ability to anticipate, avert, and contain resistance. The study also aims to 
initiate appropriate actions to be adopted as soon as possible.  
The author wanted to document the prevalence of aminopenicillin and met-
ronidazole resistance among 18 selected oral bacteria. The presence of aminopenicil-
lin- and metronidazole-resistant oral bacteria in dental practice is worrisome, princi-
pally because these antimicrobials are used most frequently by dentists, as revealed in 
the current study, for empiric therapy in many encountered oral infections [47, 51, 
129].  
At the beginning of this study, ampicillin was chosen for the performance of 
aminopenicillins susceptibility testing for investigating the prevalence of resistance to 
these agents among the studied subgingival species. On proceeding with the dentists’ 
antimicrobial prescription practices, the author, unexpectedly, discovered that am-
picillin is not one of the antimicrobials utilized by dentists in Norway. This unex-
pected discovery was further investigated to disclose reasons behind dentists’ zero-
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ampicillin-prescriptions. It was found that only one formulation exists in Norway for 
ampicillin, that is, injection. The existence of only this form of ampicillin explains the 
zero-ampicillin-prescriptions by Norwegian dentists, principally because dentists in 
Norway do not prescribe injections. Nevertheless, the issue was not of big concern, 
because the ampicillin resistance prevalence obtained earlier in paper 1 is also valid 
for amoxicillin [130], which is prescribed frequently by dentists. 
5.2 Specific discussion  
Prevalence of resistance and resistance determinants 
The occurrence of the 18 studied oral bacteria in the two study groups varies 
with some significant differences. These differences are in line with studies that have 
shown differences in the mean proportions of subgingival species in samples from 
periodontitis or healthy subjects in different countries, which may be explained by 
variations in oral hygiene, race, age, diet, genetics, disease susceptibility, and disease 
manifestations [131-134]. There were significant differences in the prevalence of am-
picillin and metronidazole resistance among the studied oral bacteria between Yemen 
and Norway with higher resistance found in Yemen. In fact, this result was somewhat 
expected owing to the presence of many risk factors that fuel resistance emergence in 
Yemen. The huge misuse and easy access of antimicrobials were observed by many 
health workers before conducting this study. However, such observations were not 
scientifically documented.  
The present situation of high resistance among oral bacteria in Yemen moves 
dentists into a vicious circle. Increasing levels of resistance necessitate the use of 
broader and more potent antimicrobials to secure patients, but using these broader 
and more potent antimicrobials exacerbates the problem of bacterial resistance, 
especially if misuse is common, and even more resistance develops and creates a 
situation where effective antimicrobials become more difficult to obtain, is expensive, 
or even lacking.  
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The bacterium F. nucleatum was chosen for a further investigation (paper 2) to 
elucidate its resistance determinants to ampicillin. Several reasons existed behind this 
selection. Firstly, F. nucleatum is an important oral microorganism and its importance 
is mentioned in the introduction section of this thesis. Secondly, β-lactam resistance 
in F. nucleatum has been on the rise [33, 34], and although β-lactamase production 
was blamed for such resistance, interestingly, the molecular characterization of this 
enzymatic resistance was not documented or fully understood [35, 95]. The results of 
this study informed about the presence of β-lactamase enzyme in ampicillin resistant 
F. nucleatum strains isolated from Yemen. The peptide mass fingerprint spectra sig-
nificantly identify a class D β-lactamase in ampicillin-resistant F. nucleatum strains 
isolated from Yemen. The matched class D β-lactamase enzyme is recorded in the 
NCBInr protein database in 2003, and even more recently it was found in one strain 
of F. nucleatum isolated in France [135]. In addition, class D β-lactamase enzyme 
production in ampicillin-resistant F. nucleatum strains was significantly associated 
with increased synthesis of two proteins, namely enolase and ABC transporter ATP-
binding protein. However, there is no evidence that any of the involved changes seen 
in enolase and ABC transporter ATP-binding protein synthesis are actually involved 
in ampicillin resistance. 
Antibiotic prescription practices  
The results obtained from paper 3 indicated that a proper antimicrobial prescription 
practice is lacking, and antimicrobial overuse by dentists in Yemen is common. A 
relationship between high rates of antibiotic resistance and high antibiotic consump-
tion was shown, which is probably related to higher consumption driving more selec-
tive pressure, and it has been noticed that after introduction of an antibiotic, clinical 
resistance has emerged [99]. The obtained results of high resistance prevalence found 
among the studied oral bacteria in Yemen with the poor knowledge of proper pre-
scribing and misuse of antimicrobial by dentists in the country are in line with the 
previously reported association between these two situations, that is, high antimicro-
bial consumption and high bacterial resistance [96-98]. However, the antimicrobials 
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use in dental practice is much less than that in medical practice. Thus, it is most prob-
able that the selective pressure applied on oral bacterial population by the use of an-
timicrobials in dental practice is less than that applied by medical practitioners. 
Therefore, the high prevalence of resistance found among oral bacteria in Yemen 
compared to Norway could not be attributed only to dentists’ misuse of 
antimicrobials in the country. Instead, dentists’ misuse of antimicrobials in Yemen 
could explain, only in part, the high prevalence of resistance found among oral 
bacteria. Most importantly, it is the probable antimicrobial misuse by other health 
workers in the country. Unfortunately, only a few reports highlight antimicrobial 
misuse by health workers in Yemen [136, 137]. 
On the other hand, a conservative antimicrobial prescribing practice prevails in 
Norway. This is observed by the strong trend of prescribing the narrow-spectrum 
penicillin phenoxymethylpenicillin by little more than 70% of all the prescriptions 
analyzed. The reliance of dentists in Norway on phenoxymethylpenicillin as their 
first choice confirms the result of low prevalence of antibiotic resistance among oral 
bacteria in Norway. The high frequency of prescribing narrow-spectrum penicillins in 
dental practice in Norway is in line with the general trend in the country [138].  
The low prevalence of ampicillin resistance among the studied subgingival 
species in Norway could be explained by the antimicrobial prescription practices re-
vealed in the current study. In Norway, the aminopenicillins prescriptions issued by 
dentists, and even by medical practitioners, are much less than that of the narrow-
spectrum penicillins prescriptions, which may suggest that the selection pressure, as a 
fundamental force in the emergence of resistant bacteria, applied on bacterial popula-
tions because of aminopenicillins use, is considerably low in the country. In addition, 
it was found that the average number of prescriptions per dentist per week, during the 
study period, is 0.59. The reported figures from United Kingdom and Canada are 3 
and 4.45, respectively [45, 54]. This finding is regarded as an additional reflection of 
the Norwegian dentists’ conservative and restricted practice in using antimicrobials. 
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Conclusions 
1. High prevalence of oral bacteria in Yemen being resistant to ampicillin and 
metronidazole compared to Norway. 
2. The high prevalence of resistant oral bacteria in Yemen is explained, at least in 
part, by the common misuse of antimicrobials by Yemeni dentists.  
3. A newly recorded class D β-lactamase is produced by ampicillin-resistant F. 
nucleatum isolates from Yemen. This enzyme could complicate antimicrobial 
treatment because these enzymes might present resistance to several classes of 
β-lactam antibiotics. 
4. The presence of conservative antibiotic prescription practices by dentists in 
Norway  
5. The continued reliance on narrow-spectrum penicillins prescriptions suggests 
that oral bacterial resistance is rare in the country. 
 
Reflections on the current situation of antibiotic resistance and recom-
mendatory suggestions to the health policy makers in Yemen 
Antimicrobials resistance by microbes is an issue of great concern. It is not a disease 
by itself but could be a part in any infectious disease treatment course. It can exacer-
bate the underlining patient conditions, from simple wound infection to car accidents. 
The emergence of multidrug resistance microbes make it even worse and more chal-
lenging for the treatment of these super-bugs. Besides the medical consequences, an-
tibiotic resistance is associated with large costs to society. The most concrete example 
and the easiest to measure is the cost of drugs, as new empirical treatments are 
needed to combat resistant pathogens. Among other factors that influence the cost are 
increased period of hospitalization, increased risks of complications and mortality, 
costs associated with isolation of patients, and the need to temporarily dismiss 
carriers of resistant bacteria within the medical staff. 
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In the recent years, understanding of how microbes resist these miracle drugs 
has made health professionals more cautious in handling and using these drugs, and 
national polices were established to guide prescribers on when and how these agents 
should be used. This is mainly true for the developed countries, where their use and 
access is very controlled. However, the use of antimicrobials and their easy access is 
still a problem in most developing countries. On the other hand, it is true to say that 
polices aimed to regulate antimicrobials (prescription, sale, handling, etc.) exists in 
many developing countries, but their implementation is not in place. As a result, mis-
use of these agents in developing countries is huge, and such presence of antimicro-
bial polices proves to be of no actual benefit in these societies.  
Halting resistance development and saving antimicrobials effectiveness need 
strict, practical, and feasible approaches. The author hereby would like to give a brief 
message to health policy makers in Yemen and argue for the urgent need to have an 
action plan for the halt of antimicrobial resistance in the country. The author proposes 
the following strategy to be adopted in Yemen for the control of antimicrobial resis-
tance: 
• Prevention: prevention of communicable diseases and infection control to re-
duce the needs for antimicrobial agents. 
• Surveillance: the establishment of a proper antimicrobial resistance surveil-
lance system in several major hospitals in the country is a crucial step that is 
lacking in the country.     
• Antimicrobials committee and subcommittees: The establishment of a 
multidisciplinary committee that monitors antimicrobial use in the country and 
implementation of policies that ban the access of antimicrobials without pre-
scriptions to improve the present resistance situation in Yemen. In addition, 
organizing antimicrobial teams in health academic institutes would ensure that 
medical education is following antimicrobial guidelines. Furthermore, these 
teams could closely monitor authorized prescribers’ practices and knowledge 
on proper prescribing.   
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• International cooperation: an effective strategy requires close cooperation 
and consultation between Yemen and other involved parties at both national 
and international levels. 
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6. Methodological considerations  
Sampling and samples transportation (papers 1 and 2) 
Traditionally, subgingival samples have been taken using either a curette or paper 
points and some variations have been documented between and even within these 
sampling methods [139, 140]. In line with this, a recent review points out that a cu-
rette collects plaque from the entire pocket, whereas plaque that is adsorbed onto a 
paper point is derived mostly from the outer layers of the biofilm, which may contain 
higher proportions of putative pathogenic bacteria relative to curette samples [141]. 
In addition, the paper points sampling is a less invasive procedure than sampling by 
curettes, and is the preferred method, especially when sampling from healthy 
periodontal pockets [139]. Therefore, paper points sampling was preferred in this 
study for the analysis of samples by the checkerboard DNA-DNA hybridization 
method using whole genomic probes. 
 For transportation of microbial samples, an ideal transport medium keeps the 
microbes alive and preserves their proportions in the sample. Anaerobiosis and low 
redox potential of the transport media is essential for survival of anaerobes [126]. In 
this study, the transport media VMGA III was chosen because of its superior proper-
ties, especially for preservation of anaerobes. 
DNA-DNA checkerboard hybridization technique (paper 1) 
Species identification was carried out using a whole genomic DNA-DNA hybridiza-
tion approach in checkerboard format [10], which is an acknowledged method for 
species identification for complex microbial populations such as oral flora. The 
checkerboard design enables the analysis of a wide range of bacteria (up to 40) in a 
large number of samples (up to 40) in one run. The sensitivity of the assay is in the 
range of 104 bacterial cells [142]. However, this technique has its disadvantages. 
Firstly, the detection is semiquantitative and is limited to species for which probes are 
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available. Secondly, the technique employs whole genomic DNA probes, which may 
increase the probability of cross-reactions between closely related species. In this 
study, hybridization signals were interpreted as true positive reactions when they 
were stronger than those of the standard 105 cells thus minimizing false positive 
readings caused by cross-reactions between DNA related species. 
Antimicrobial susceptibility testing (papers 1 and 2) 
The purpose of undertaking susceptibility testing, by whatever method, is to attempt 
to establish and integrate the pattern of in vitro potency of an antimicrobial agent 
against a population of potential pathogens into a relationship in the light of clinical 
experience. Thus breakpoints, discriminatory antimicrobial concentrations were used 
in the interpretation of results of susceptibility testing to define isolates as 
susceptible, intermediate, or resistant. In the United States, the Clinical and 
Laboratory Standard Institute (CLSI) - previously called the National Committee for 
Clinical Laboratory Standards (NCCLS) - publishes consensus standards and 
guidelines for susceptibility testing that are adopted in many parts of the world. These 
standards and susceptibility breakpoints have undergone considerable changes from 
the late 1970s and up to the present. Within Europe, the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST), which is a standing committee of 
the European Society for Clinical Microbiology and Infectious Diseases (ECCMID), 
adopted two separate breakpoints [143]. The first one depends on the normal 
distribution of bacteria’s MICs and is named epidemiological cut-off. It aims at 
detecting bacteria with resistance mechanisms and at monitoring development of 
resistance. The second breakpoint is known as clinical breakpoints and is intended for 
the guidance of therapy. The epidemiological cut-off breakpoint defines an organism 
as resistant (non-wild type) if the observed MIC or inhibition zone falls outside the 
normal distribution of MICs or zones for isolates without specific resistance 
mechanisms (wild type). Therefore, it automatically gives importance to small 
reductions in bacterial susceptibility and allows emerging low-level resistance to be 
detected and monitored. 
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In this thesis, one of the main objectives was to document the prevalence of 
aminopenicillins and metronidazole resistant-subgingival species, in both Yemen and 
Norway, for comparison rather than for clinical oriented aims. Therefore, the epide-
miological cut-off breakpoint was thought best suitable for use in the current study to 
compare resistance prevalence in Yemen and Norway. However, the epidemiological 
cut-off breakpoints of the 18 investigated subgingival spices were not reported by the 
EUCAST. Nevertheless, the author adopted a breakpoint of 2 µg/mL for both am-
picillin and metronidazole in the study based on literature review [24, 144-148]. This 
concentration is higher than the in vitro MIC90s (i.e. the MIC of an antimicrobial 
agent that inhibits the growth of 90% of susceptible isolates) values shown in the in 
vitro susceptibility studies of oral bacteria referred to in the study. Ampicillin and 
amoxicillin are aminopenicillins with the same broad antimicrobial spectrum; how-
ever, for the susceptibility testing ampicillin was chosen. This decision was based 
only on practical reasons, provided that results from antimicrobial resistance testing 
with one of them is valid for the other one as well [130]. 
 The E-test (AB Biodisk, Sweden) has been shown to be a reliable method for 
antimicrobials MICs determinations of isolated bacterial strains, with results compa-
rable to those obtained by the NCCLS methods [16]. Therefore, this method was used 
to determine the ampicillin MIC values of the 23 F. nucleatum strains isolated from 
Yemen. 
Proteome analysis (paper 2) 
The word proteomics was first introduced in 1995 and was defined as the large-scale 
characterization of the entire protein complement of a cell line, tissue or organism. 
Proteome analysis is a direct measurement of proteins in terms of their presence and 
relative abundance. The introduction of the two-dimensional gel electrophoresis (2-
DE) method in 1975 by O’Farrell and its development was a major step forward in 
protein separation. Today, the 2-DE with immobilized pH gradients for proteins sepa-
ration and the subsequent identification of these proteins by MALDI-TOF mass spec-
trometry is one of the techniques preferred for proteomic studies in Europe. However, 
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the technique has its disadvantages and limitations. Generally, it is a time consuming 
technique; the general workflow of the experiment could last several days. Moreover, 
sample preparation for 2-DE could be problematic, especially to achieve a desirable 
degree of solublization for hydrophobic proteins such as membranous proteins. In 
addition, the detection threshold of the resolved proteins in the gel is limited by the 
sensitivity of the used stain, so low abundance-proteins could be difficult to detect 
and analyze.  
 Optimization of the 2D-E technique to better resolve and analyze the proteins 
of F. nucleatum took a considerable time, especially to deal with and reduce the 
streaking business, until satisfactory 2D-E images were obtained. In addition, the 
subsequent analysis of F. nucleatum proteome maps was confronted by, but not 
limited to, the heterogeneity of the F. nucleatum strains. Thus, it was concluded that a 
significant proportion of the variability in the observed proteome between the 
ampicillin-susceptible and ampicillin-resistant F. nucleatum strains was unrelated to 
differences in ampicillin resistant phenotype and was because of background strain 
variation. 
Antibiotic prescription practices (papers 3 and 4) 
Two different approaches were used to investigate dentists’ antimicrobial prescription 
practices in Yemen and Norway for any possible contribution on the emergence of 
bacterial resistance. In Yemen, obtaining real prescription data is rather difficult, if 
not impossible. This is principally because of a lack of prescriptions registry 
database. Therefore, the approach to retrieve information about Yemeni dentists’ 
antimicrobial prescription practices was based on investigating their knowledge of 
conditions for the proper prescribing of antimicrobial agents to their patients. On the 
other hand, prescriptions registration database, namely NorPD, exists in Norway 
[149]. The dentists’ prescriptions data is stored and systematized in NorPD to enable 
researchers to retrieve information on frequencies of antibiotic prescriptions by 
dentists, but most importantly, the data is aggregated using the WHO antibiotic 
consumption unit known as DDD [124]. The data stored in NorPD lacks information 
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on doses used, frequency of administration, duration of treatment, and reasons for 
individual prescriptions. Such missing information would have also reflected on the 
knowledge for proper prescribing. However, knowledge for proper prescribing 
among dentists in Norway was investigated [150, 151], and these studies revealed a 
general good prescription knowledge. Therefore, the use of the available data stored 
in NorPD was considered sufficient to satisfy one of this study’s main aims, that is, 
assessing dentists’ antimicrobial prescription practices.  
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Abstract
The purpose of this study was to assess the prevalence of resistance to aminopenicillins and metronidazole among selected subgingival
species in dental patients from Yemen and Norway. Three subgingival samples were collected by paper points from each of 34 Yemeni and 21
Norwegian adult volunteers and then pooled. Each of the 55 pooled samples was plated on fastidious anaerobic blood agar containing 2g/mL
ampicillin or metronidazole, or no antimicrobial. Species identification of growth was done using DNA–DNA checkerboard hybridisation.
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dhe overall proportion of ampicillin resistance among the 18 identified species was 28.9% and 7.9% in the Yemeni and Norwegian samples,
espectively, whereas for metronidazole it was 60.3% and 11.3%. The number of species resistant to ampicillin and metronidazole was
ignificantly higher (P < 0.016 and P = 0.0000, respectively) in the Yemeni than in the Norwegian samples.
2005 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
eywords: Antimicrobial resistance; Developing countries; Oral bacteria
. Introduction
The oral flora is comprised of more than 600 cultivable
nd non-cultivable species [1]. In certain conditions and when
he ecology of the oral microbiota is disturbed, a subset of
hese species become virulent and cause infections. Utilising
ntimicrobial agents is one way to fight such infections. How-
ver, like most medically significant bacteria, antimicrobial
esistance among oral bacteria is an evolving problem. Sev-
ral studies on susceptibility testing of oral bacteria reported
he presence of isolates that were resistant to penicillin,
etronidazole, tetracycline and macrolides [2]. Antimicro-
ial resistance is a global problem and one of the biggest
hallenges facing public health today [3]. The problem is
omplex and multifactorial [4–6] and also of increasing con-
ern to dentistry [2,7]. Development of antimicrobial resis-
ance mechanisms by pathogenic microorganisms is their way
o evade antimicrobials and thus survive [8].
∗ Corresponding author. Tel.: +47 55 97 57 84; fax: +47 5597 4979.
E-mail address: Mohammed.Al-Haroni@student.uib.no
Most studies that deal with the emergence of antimi-
crobial resistance of oral bacteria have been done in the
western world. Little information is therefore available from
developing countries. Yemen, like most developing coun-
tries, possesses socioeconomic and behavioural factors that
promote bacterial resistance [9]. In Yemen, self-prescription
by individuals and misuse due to healthcare provider-related
factors are common practices [10]. Data from Yemen are
sparse and the few published reports regarding bacterial
resistance call for urgent need of national surveillance [11].
On the other hand, to the best of our knowledge there is
only one report from Norway regarding antibiotic resis-
tance of oral bacteria [12]. This study found that 68% of
25 patients with refractory marginal periodontitis harboured
-lactamase-producing bacteria.
Our aim was to assess the prevalence in a develop-
ing country (Yemen) and a developed country (Norway) of
selected subgingival bacteria resistant to aminopenicillins
and metronidazole, two antimicrobials commonly prescribed
by dentists [13–16], to determine whether the information in
the literature regarding antimicrobial-resistant human medi-
cal bacteria in the two countries is also valid for oral bacteria.M.H. Al-Haroni).
924-8579/$ – see front matter © 2005 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
oi:10.1016/j.ijantimicag.2005.10.011
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2. Materials and methods
2.1. Study subjects
Thirty-four Yemeni dental patients (mean age 30.1 ± 1.9
years) who visited three dental clinics in Sana’a, Yemen, dur-
ing the summer of 2003, and 21 Norwegian dental patients
(mean age 40.4 ± 2.3 years) who visited two clinics in
Bergen, Norway, during the spring of 2004 were recruited
for the study. All patients were in need of dental treatment
and were selected consecutively among volunteers. Subjects
were excluded from the study if they: (1) had general medical
problems known to influence their subgingival microflora;
(2) suffered from aggressive periodontitis or acute necro-
tizing gingivitis or periodontitis; and/or (3) had taken any
antimicrobial(s) during the last 3 months prior to sampling.
Sampling and examination of the samples were approved by
the Regional Committee for Medical Research Ethics, West
Norway.
2.2. Subgingival sampling
After clinical examination and removal of supragingival
plaque, three randomly selected posterior teeth in each patient
were assigned for isolation and subgingival sampling. The
s
s
a
s
t
V
w
a
D
2
U
t
e
F
Thereafter, 10L of each sample suspension was plated on
fastidious anaerobic blood agar (Lab M, Bury, UK) with
either 2g/mL ampicillin or 2g/mL metronidazole, or with
no antimicrobial [18]. The inoculated plates were incubated
anaerobically (5% CO2, 10% H2 and 85% N2) for 10 days at
37 ◦C using the Anoxomat SystemTM (MART Microbiology
BV, Lichtenvoorde, The Netherlands).
After incubation, the growth on each plate was suspended
in 1 mL TE buffer (10 mM Tris–HCl and 1 mM EDTA, pH
7.6) using sterile L-shaped plastic rods before being trans-
ferred into individual sterile 10 mL glass tubes and sonicated
for 10 s to disintegrate clumps. For standardisation, optical
density at 600 nm (OD600) of the suspensions was adjusted to
a final OD600nm of 1.0 (≈109 cells/mL). To prepare samples
for analysis, 10L of each adjusted suspension (≈107 cells)
was transferred to individual Eppendorf tubes, each contain-
ing 140L TE buffer. All the Eppendorf tubes were stored
at 5 ◦C.
2.4. Preparation of DNA probes
The 18 probe species (Table 1) were cultivated, harvested
and prepared for DNA extraction as explained elsewhere [19].
DNA extraction was performed according to the method of
Smith et al. [20]. The quantity of extracted DNA was deter-
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Gubgingival samples were collected using sterile paper points
ize 50 (Dentsply, York, PA, USA) that were inserted as far
s possible subgingivally and removed after 20 s. The three
amples obtained from each subject were pooled by placing
hem in a sterile vial containing 1.5 mL of locally produced
MGA III transport medium [17]. All the pooled samples
ere transported at ambient temperature in plastic bags under
naerobic condition using the Anaerocult® system (Merck,
armstadt, Germany).
.3. Cultivation of samples
Samples arrived at the Laboratory of Oral Microbiology,
niversity of Bergen within 48 h after sampling. On arrival,
hree to five sterile glass beads were added aseptically to
ach vial. The samples were then vortexed (WhirliMixer;
isons Scientific Equipment, Loughborough, UK) for 2 min.
able 1
acterial strains used for preparation of whole genomic DNA probes
pecies Strains
orphyromonas gingivalis ATCC 33277
revotella intermedia VPI 4197
ctinobacillus actinomycetemcomitans ATCC 33384
ikenella corrodens ATCC 23834
ampylobacter rectus ATCC 33238
apnocytophaga gingivalis ATCC 33624
usobacterium nucleatum ATCC 23736
eptostreptococcus micros CCUG 17638
treptococcus mutans ATCC 25175
TCC, American Type Culture Collection, USA; VPI, Virginia Polytechn
othenburg, Sweden; FDC, Forsyth Dental Center, Boston, USA.ined spectrophotometrically as the absorbance at 260 nm
nd its purity as the ratio of absorbance at 260 nm and 280 nm.
ratio of 1.8 corresponds to DNA of 100% purity. DNA
ith at least 90% purity was accepted for probe prepara-
ion. Whole genomic DNA probes were prepared from each
train by labelling 1–3g of DNA with digoxigenin (DIG-
igh prime; Roche Diagnostics, Basel, Switzerland) using the
andom primer technique [21].
.5. Identiﬁcation of probe species in the samples
The samples were analysed using whole genomic DNA
robes and DNA–DNA checkerboard hybridisation [22]. In
rief, the prepared samples were lysed and vacuum-filtered
nto a 15 cm × 15 cm positively charged nylon membrane
sing the ‘Minislot-30’ device (Immunetics, Cambridge,
A). Two pooled standards containing 1 ng and 10 ng of
Species Strains
Streptococcus oralis ATCC 10557
Streptococcus sanguinis ATCC 10556
Streptococcus constellatus ATCC 27823
Streptococcus gordonii CCUG 33482
Streptococcus mitis ATCC 9811
Streptococcus intermedius ATCC 27335
Tannerella forsythensis FDC 2008
Veillonella parvula ATCC 10790
Eubacterium nodatum CCUG 15996
ute and State University, USA; CCUG, Culture Collection, University of
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DNA corresponding to 105 and 106 bacteria [23], respec-
tively, of each probe species were included in each run.
The membranes were allowed to dry at room temperature
and the samples were fixed by exposure to 70 mJ/cm2 of
ultraviolet light. The membranes were pre-hybridised and
then hybridised with the digoxigenin-labelled whole genomic
DNA probes using the ‘Miniblot 45’ device (Immunetics).
Hybrids were detected by chemiluminescence as described
by Wall-Manning et al. [23] except that skim milk was used
instead of casein in the blocking solution and the stringency
washes were performed in sodium dodecyl sulfate (SDS)
buffer (0.1% sodium chloride sodium citrate, 0.1% SDS).
Hybridisation signals were interpreted as true-positive reac-
tions when they were stronger than those of the standard
105 cells, thus minimising false-positive readings caused by
cross-reactions between DNA-related species.
2.6. Statistical analysis
Data available for each individual were: (1) absence/
presence of each probe species, recorded as 0/1; (2)
absence/presence of each resistant species, recorded as 0/1;
and (3) number of all resistant species detected, recorded
from 0 to 18 as appropriate. The overall resistance among
the probe species was calculated by dividing the total num-
ber of resistant species detected for each antimicrobial with
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Fig. 1. Percentages of the probe species testing positive in the two study
populations. *P < 0.05.
exhibited a significantly higher prevalence of metronidazole-
resistantEikenella corrodens,Streptococcusmutans,Strepto-
coccus oralis,S. sanguinis,Streptococcus constellatus,Strep-
tococcus gordonii, S. mitis, Streptococcus intermedius and V.
parvula (Fig. 2A) as well as a significantly increased preva-
lence of ampicillin-resistantP. gingivalis,Prevotella interme-
dia, S. constellatus, S. intermedius, Tannerella forsythensis,
Fusobacterium nucleatum and V. parvula (Fig. 2B). The most
frequently detected species in the Yemeni samples resistant
to both antibiotics was V. parvula.
4. Discussion
Our aim was to assess the resistance to two commonly used
antimicrobials (aminopenicillin and metronidazole) among
18 subgingival species in adults who visited a dental clinic in
Yemen or Norway for various reasons. Most previous stud-
ies on antimicrobial resistance of oral bacteria referred to
periodontitis patients [12,24]. Few of the sample donors in
our study suffered from periodontitis. By using paper points,
subgingival planktonic bacteria and loosely attached dental
biofilm, which contains the more pathogenic microflora [25],
were sampled. Our data provide information regarding the
prevalence of the 18 probe species in the subgingival micro-
biota of these subjects. The significant differences in this
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the total number of species shown. The two study groups
ere compared for prevalence of probe species as well as
esistant ones using the χ2 test. Differences in resistance to
oth drugs between the two groups were sought using the
ann–Whitney U-test. Differences with P < 0.05 were con-
idered statistically significant. SPSS 12.0 for Windows was
sed for computerisation and statistical analysis.
. Results
.1. Prevalence of the probe species
All the probe species were detected in subgingival samples
rom both patient groups, but at different frequencies (Fig. 1).
orphyromonas gingivalis, Eubacterium nodatum, Strepto-
occus sanguinis and Veillonella parvula were significantly
P < 0.05) more prevalent in the Yemeni subjects, whilst Acti-
obacillus actinomycetemcomitans, Capnocytophaga gingi-
alis and Streptococcus mitis showed a significantly higher
revalence in the Norwegian samples.
.2. Prevalence of resistant species
In the samples from the Yemeni subjects, 28.9% and
0.3% of all detected species were resistant to ampicillin and
etronidazole, respectively. The corresponding figures for
he Norwegian samples were 7.9% and 11.3%. Fig. 2 shows
he prevalence of individual species resistant to ampicillin
r metronidazole in the two study groups. Yemeni samplesegard between the Yemeni and Norwegian dental patients
re in line with studies that have shown differences in the
ean proportions of subgingival species in samples from
eriodontitis or healthy subjects in different countries, which
ay be explained by differences in oral hygiene, race, age,
iet, genetics as well as disease susceptibility and manifes-
ations [26–28].
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Fig. 2. Prevalence of the probe species resistant to (A) 2g/mL metronidazole and (B) 2g/mL ampicillin in the two study populations. *P < 0.05.
Ampicillin and amoxicillin are aminopenicillins with the
same broad antimicrobial spectrum [29] and results from
antimicrobial resistance testing with one of them is also
valid for the other [30]. Aminopenicillins are one of the
three antimicrobials most commonly prescribed in dentistry
[31]. The proportion of ampicillin-resistant species was sig-
nificantly higher in Yemeni than in Norwegian subgingival
samples (28.9% versus 7.9%). Previously, a very small pro-
portion of the subgingival microbiota has been found to be
resistant to penicillins in vitro [29,32,33]. Recently, Feres et
al. [18] reported the percentage of bacterial isolates resistant
to amoxicillin in subgingival plaque samples at baseline to
be 0.5%. During 14 days of amoxicillin treatment, the preva-
lence of resistant isolates increased to 37% and dropped to
baseline levels 76 days post treatment. Since the subjects in
our study confirmed not having taken any antimicrobial dur-
ing the 90 days prior to sampling, they harboured permanently
resistant species.
Our findings of 19.4% and 3.3% ampicillin-resistant strep-
tococcal isolates in the Yemeni and Norwegian samples,
respectively, are in line with the high levels of penicillin resis-
tance that are now being demonstrated in the -haemolytic
streptococci [2]. Diaz-Mejia et al. [34] tested the ampicillin
susceptibility of oral streptococci from healthy Cuban and
Mexican volunteers and found the proportion of resistant
strains to be less than 5%. More recently, it was reported
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periodontal pockets [36,37]. In the Yemeni samples, all the
Prevotella isolates were resistant to ampicillin. Furthermore,
ampicillin-resistant P. gingivalis was detected in 15 Yemeni
samples but in none of the Norwegian ones. The suscepti-
bility of P. gingivalis to penicillins has been reported to be
100% [24,38] and the bacterium has so far not been reported
to produce -lactamase [12,38–40] or to have -lactamase
genes [41]. However, Prieto-Prieto and Calvo [42] referred to
a study conducted in Spain in which 59% of Porphyromonas
species were resistant to penicillin G; Spain is known to have
high antibiotic consumption [24].
Metronidazole is mainly active against strict anaerobes
[43,44] and dentists are frequent prescribers of this antimi-
crobial [45]. Susceptible organisms rarely develop resis-
tance to metronidazole, but some species may require a
high concentration for susceptibility [46]. The proportions
of metronidazole-resistant species in the Yemeni and Nor-
wegian samples were 60% and 11%, respectively. In com-
parison, Feres et al. [18] reported that over 50% of the
isolates in their study were resistant to 2g/mL metron-
idazole in vitro prior to administration of that agent. As
expected, the streptococci species comprised a high pro-
portion (84% and 8% from Yemen and Norway, respec-
tively) of the metronidazole-resistant species in the current
study; aerobic bacteria can utilise the aerobic metabolism
pathway and consequently bypass the crucial reduction step
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Hhat the susceptibility rate of viridans group streptococci to
mpicillin was 95% [35], giving a proportion of resistant iso-
ates similar to that reported in our study from Norway as
ell as reported from Mexico and Cuba [34].
The species that accounted for the significantly increased
roportion of ampicillin-resistant species in the Yemeni sam-
les compared with the Norwegian samples were P. inter-
edia, V. parvula, A. actinomycetemcomitans, T. forsythen-
is and P. gingivalis. -Lactamase production by Prevotella
pecies is well known and such species have been reported
o be the most frequent -lactamase-producing species in thentracellularly that is required for this drug to be active
47]. However, V. parvula, which is an obligate anaerobe
hat has been reported to be highly sensitive to metron-
dazole [18,24], was frequently detected as metronidazole
esistant in the Yemeni subjects. Recently, and in line with
ur findings, one study has shown that treatment of Heli-
obacter pylori with metronidazole-based triple therapy in
emen was unsatisfactory [48]. This finding was attributed
o the misuse of metronidazole in the country and subsequent
acterial resistance that affected complete eradication of
. pylori.
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The proportion of resistant isolates demonstrated in vitro
in microbiological samples will depend on the concentra-
tion of the antimicrobial agent used for growth inhibition
and the interspecies variability in susceptibility to that agent.
It was recently concluded that the interindividual suscep-
tibility of principal periodontal pathogens is not homoge-
neous and appears to vary according to bacterial species and
antimicrobial molecules [49]. This variability seemed to be
greater with older agents than with newer ones (e.g. ampi-
cillin and amoxicillin). In our study, we adopted a breakpoint
of 2g/mL for both ampicillin and metronidazole. This con-
centration is higher than the in vitro MIC90 values (i.e. the
minimum inhibitory concentration of an antimicrobial agent
that inhibits the growth of 90% of susceptible isolates) shown
in the in vitro susceptibility studies of oral bacteria referred to
in our study [50–55]. Thus, 2g/mL theoretically falls out-
side the normal distribution of MICs for each of the species
under the current study.
The definition of microbial resistance is a tenuous issue
and a topic of debate. Therefore, the term breakpoint was
established to define the borderline between susceptible and
resistant isolates. However, from the late 1970s up to now,
such breakpoints have undergone considerable changes. The
European Committee on Antimicrobial Susceptibility Test-
ing (EUCAST) adopted recently two separate breakpoints
[56]. The first one, depending on the normal distribution of a
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prescription of antibiotics are common practices [10]. A hor-
rifying example of the latter practice was a patient excluded
from our study who reported daily use of an antibiotic just
to increase his appetite. In fact, it was a difficult task to find
Yemeni subjects who fulfilled the inclusion criteria of our
study. However, like in most developing countries, socioe-
conomic and behavioural factors also lead to and promote
bacterial resistance [9].
In conclusion, this is the first report on ampicillin and
metronidazole resistance among the subgingival microbiota
in Yemen. The results indicate a high prevalence of oral bacte-
ria in Yemen with resistance to ampicillin and metronidazole.
This difference is probably attributed to easy access, mis-
use and availability of poor quality drugs in the country. In
contrast, this is a limited problem in Norway. Our findings
should be taken into consideration when managing oral infec-
tions as well as extraoral infections of oral origin in Yemeni
patients.
Acknowledgments
We would like to thank Dr Arhab Noman for his help
during data collection. This study was supported by the Nor-
wegian Loan Fund for Education.
R
[
[
[acteria’s MICs and named the epidemiological cut-off, aims
t detecting bacteria with resistance mechanisms and at mon-
toring development of resistance. The second breakpoint is
nown as the clinical breakpoint and is intended for guidance
f therapy.
Lack of harmonisation of breakpoints and methods creates
ifficulties in the comparison of our results of proportions of
esistant molecular isolates with those of the other studies.
eres et al. [18] and Rodrigues et al. [57] identified and deter-
ined the percentages of resistant species in the same way
s was done in our study. However, Feres et al. [18] related
he proportions of resistant isolates to individual sample sites
hilst in our study the results are related to one pooled sample
er individual. In the Rodrigues et al. study [57], four peri-
dontal pockets were sampled per individual and the mean
ercentage of tetracycline-resistant isolates was computed
y averaging these values within a subject and then in each
reatment group at each visit.
Limitations of the current study are that: no MICs could
e established for the isolates; isolates that might have been
esistant to both 2g/mL ampicillin and 2g/mL metron-
dazole could not be revealed; and resistant isolates could
ot be harvested and stored. However, our findings did dis-
lose significant differences in the in vitro prevalence of
mpicillin- and metronidazole-resistant subgingival species
etween Yemen and Norway. These differences can be
ttributed to the different levels of factors promoting micro-
ial resistance in the two countries. In Norway, usage of
ntimicrobials is well controlled and probably low compared
ith Yemen where misuse by health professionals and self-eferences
[1] Kazor CE, Mitchell PM, Lee AM, et al. Diversity of bacterial pop-
ulations on the tongue dorsa of patients with halitosis and healthy
patients. J Clin Microbiol 2003;41:558–63.
[2] Sweeney LC, Dave J, Chambers PA, Heritage J. Antibiotic resistance
in general dental practice — a cause for concern? J Antimicrob
Chemother 2004;53:567–76.
[3] WHO report on infectious diseases. Wkly Epidemiol Rec 1999;
74:279.
[4] Byarugaba DK. A view on antimicrobial resistance in develop-
ing countries and responsible risk factors. Int J Antimicrob Agents
2004;24:105–10.
[5] Pallasch TJ. Global antibiotic resistance and its impact on the dental
community. J Calif Dent Assoc 2000;28:215–33.
[6] Pallasch TJ. Global antibiotic resistance and its impact on the dental
community. J N J Dent Assoc 2000;71:14–5, 18–9, 22–3 passim.
[7] Stefanopoulos PK, Kolokotronis AE. The clinical significance of
anaerobic bacteria in acute orofacial odontogenic infections. Oral
Surg Oral Med Oral Pathol Oral Radiol Endod 2004;98:398–408.
[8] McKeegan KS, Borges-Walmsley MI, Walmsley AR. Microbial and
viral drug resistance mechanisms. Trends Microbiol 2002;10(10
Suppl.):S8–14.
[9] Okeke IN, Lamikanra A, Edelman R. Socioeconomic and behav-
ioral factors leading to acquired bacterial resistance to antibiotics in
developing countries. Emerg Infect Dis 1999;5:18–27.
10] Al-Maktari MT, Bassiouny HK. Malaria status in Al-Hodeidah Gov-
ernorate, Republic of Yemen. Part II: Human factors causing the
persistence of chloroquine resistant P. falciparum local strain. J
Egypt Soc Parasitol 2003;33:829–39.
11] Banajeh SM, Ba-Oum NH, Al-Sanabani RM. Bacterial aetiology and
anti-microbial resistance of childhood diarrhoea in Yemen. J Trop
Pediatr 2001;47:301–3.
12] Handal T, Caugant DA, Olsen I. Antibiotic resistance in bacteria
isolated from subgingival plaque in a Norwegian population with
222 M.H. Al-Haroni et al. / International Journal of Antimicrobial Agents 27 (2006) 217–223
refractory marginal periodontitis. Antimicrob Agents Chemother
2003;47:1443–6.
[13] Preus HR, Albandar JM, Gjermo P. Antibiotic prescribing practices
among Norwegian dentists. Scand J Dent Res 1992;100:232–5.
[14] Thomas DW, Satterthwaite J, Absi EG, Lewis MA, Shepherd JP.
Antibiotic prescription for acute dental conditions in the primary
care setting. Br Dent J 1996;181:401–4.
[15] Roy KM, Bagg J. Antibiotic prescribing by general dental practi-
tioners in the Greater Glasgow Health Board, Scotland. Br Dent J
2000;188:674–6.
[16] Palmer NA, Pealing R, Ireland RS, Martin MV. A study of pro-
phylactic antibiotic prescribing in National Health Service general
dental practice in England. Br Dent J 2000;189:43–6.
[17] Dahlen G, Pipattanagovit P, Rosling B, Moller AJ. A comparison
of two transport media for saliva and subgingival samples. Oral
Microbiol Immunol 1993;8:375–82.
[18] Feres M, Haffajee AD, Allard K, Som S, Goodson JM, Socran-
sky SS. Antibiotic resistance of subgingival species during
and after antibiotic therapy. J Clin Periodontol 2002;29:724–
35.
[19] Al-Hebshi NN, Skaug N. Effect of khat chewing on 14 selected
periodontal bacteria in sub- and supragingival plaque of a young
male population. Oral Microbiol Immunol 2005;20:141–6.
[20] Smith GL, Socransky SS, Smith CM. Rapid method for the purifi-
cation of DNA from subgingival microorganisms. Oral Microbiol
Immunol 1989;4:47–51.
[21] Feinberg AP, Vogelstein B. A technique for radiolabeling DNA
restriction endonuclease fragments to high specific activity. Anal
Biochem 1983;132:6–13.
[22] Socransky SS, Smith C, Martin L, Paster BJ, Dewhirst FE,
Levin AE. ‘Checkerboard’ DNA–DNA hybridization. Biotechniques
[
[
[
[
[
[
[
[
[
[
[
[34] Diaz-Mejia JJ, Carlos-Sausedo A, Amabile-Cuevas CF. Antibiotic
resistance in oral commensal streptococci from healthy Mexicans
and Cubans: resistance prevalence does not mirror antibiotic usage.
FEMS Microbiol Lett 2002;217:173–6.
[35] Chan Y, Chan CH. Antibiotic resistance of pathogenic bacteria
from odontogenic infections in Taiwan. J Microbiol Immunol Infect
2003;36:105–10.
[36] Fosse T, Madinier I, Hitzig C, Charbit Y. Prevalence of -lactamase-
producing strains among 149 anaerobic gram-negative rods iso-
lated from periodontal pockets. Oral Microbiol Immunol 1999;14:
352–7.
[37] Kononen E, Nyfors S, Matto J, Asikainen S, Jousimies-Somer H. -
Lactamase production by oral pigmented Prevotella species isolated
from young children. Clin Infect Dis 1997;25(Suppl. 2):S272–4.
[38] Walker CB. The acquisition of antibiotic resistance in the periodontal
microflora. Periodontol 2000 1996;10:79–88.
[39] Handal T, Olsen I, Walker CB, Caugant DA. -Lactamase pro-
duction and antimicrobial susceptibility of subgingival bacteria
from refractory periodontitis. Oral Microbiol Immunol 2004;19:
303–8.
[40] Herrera D, van Winkelhoff AJ, Dellemijn-Kippuw N, Winkel
EG, Sanz M. -Lactamase producing bacteria in the subgingival
microflora of adult patients with periodontitis. A comparison between
Spain and The Netherlands. J Clin Periodontol 2000;27:520–5.
[41] Handal T, Olsen I, Walker CB, Caugant DA. Detection and
characterization of -lactamase genes in subgingival bacteria
from patients with refractory periodontitis. FEMS Microbiol Lett
2005;242:319–24.
[42] Prieto-Prieto J, Calvo A. Microbiological basis of oral infections
and sensitivity to antibiotics. Med Oral Patol Oral Cir Bucal
2004;9(Suppl.):15–8, 11–4.
[
[
[
[
[
[
[
[
[
[
[1994;17:788–92.
23] Wall-Manning GM, Sissons CH, Anderson SA, Lee M. Checker-
board DNA–DNA hybridisation technology focused on the anal-
ysis of Gram-positive cariogenic bacteria. J Microbiol Methods
2002;51:301–11.
24] Van Winkelhoff AJ, Herrera Gonzales D, Winkel EG, Dellemijn-
Kippuw N, Vandenbroucke-Grauls CM, Sanz M. Antimicrobial resis-
tance in the subgingival microflora in patients with adult periodon-
titis. A comparison between The Netherlands and Spain. J Clin
Periodontol 2000;27:79–86.
25] Loomer PM. Microbiological diagnostic testing in the treatment of
periodontal diseases. Periodontol 2000 2004;34:49–56.
26] Schenkein HA, Burmeister JA, Koertge TE, et al. The influ-
ence of race and gender on periodontal microflora. J Periodontol
1993;64:292–6.
27] Moore WE, Holdeman LV, Cato EP, et al. Variation in periodontal
floras. Infect Immun 1984;46:720–6.
28] Haffajee AD, Bogren A, Hasturk H, Feres M, Lopez NJ, Socran-
sky SS. Subgingival microbiota of chronic periodontitis subjects
from different geographic locations. J Clin Periodontol 2004;31:996–
1002.
29] Walker CB, Gordon JM, Socransky SS. Antibiotic susceptibil-
ity testing of subgingival plaque samples. J Clin Periodontol
1983;10:422–32.
30] National Committee for Clinical Laboratory Standards. Performance
standards for antimicrobial susceptibility testing; Fourteenth Inter-
national Supplement. Document M100-S14. Wayne, PA: NCCLS;
2004.
31] Handal T, Olsen I. Antimicrobial resistance with focus on oral beta-
lactamases. Eur J Oral Sci 2000;108:163–74.
32] Sutter VL, Jones MJ, Ghoneim AT. Antimicrobial susceptibilities
of bacteria associated with periodontal disease. Antimicrob Agents
Chemother 1983;23:483–6.
33] Kinder SA, Holt SC, Korman KS. Penicillin resistance in the subgin-
gival microbiota associated with adult periodontitis. J Clin Microbiol
1986;23:1127–33.43] Citron DM, Ostovari MI, Karlsson A, Goldstein EJ. Evaluation of
the E test for susceptibility testing of anaerobic bacteria. J Clin
Microbiol 1991;29:2197–203.
44] Poulet PP, Duffaut D, Lodter JP. Evaluation of the Etest for deter-
mining the in-vitro susceptibilities of Prevotella intermedia isolates
to metronidazole. J Antimicrob Chemother 1999;43:610–1.
45] Standing Medical Advisory Committee. The path of least resistance.
London: Department of Health; 1998.
46] Poulet PP, Duffaut D, Lodter JP. Metronidazole susceptibility test-
ing of anaerobic bacteria associated with periodontal disease. J Clin
Periodontol 1999;26:261–3.
47] Roberts MC. Antibiotic toxicity, interactions and resistance develop-
ment. Periodontol 2000 2002;28:280–97.
48] Gunaid AA, Hassan NA, Murray-Lyon IM. Recurrence of Helicobac-
ter pylori infection 1 year after successful treatment: prospective
cohort study in the Republic of Yemen. Eur J Gastroenterol Hepatol
2004;16:1309–14.
49] Lakhssassi N, Elhajoui N, Lodter JP, Pineill JL, Sixou M. Antimi-
crobial susceptibility variation of 50 anaerobic periopathogens in
aggressive periodontitis: an interindividual variability study. Oral
Microbiol Immunol 2005;20:244–52.
50] Koeth LM, Good CE, Appelbaum PC, et al. Surveillance of suscep-
tibility patterns in 1297 European and US anaerobic and capnophilic
isolates to co-amoxiclav and five other antimicrobial agents. J
Antimicrob Chemother 2004;53:1039–44.
51] Ihalin R, Pienihakkinen K, Lenander M, Tenovuo J, Jousimies-
Somer H. Susceptibilities of different Actinobacillus actino-
mycetemcomitans strains to lactoperoxidase–iodide–hydrogen perox-
ide combination and different antibiotics. Int J Antimicrob Agents
2003;21:434–40.
52] Kuriyama T, Karasawa T, Nakagawa K, Yamamoto E, Nakamura S.
Bacteriology and antimicrobial susceptibility of gram-positive cocci
isolated from pus specimens of orofacial odontogenic infections. Oral
Microbiol Immunol 2002;17:132–5.
53] Luong N, Tsai J, Chen C. Susceptibilities of Eikenella corrodens,
Prevotella intermedia, and Prevotella nigrescens clinical isolates
M.H. Al-Haroni et al. / International Journal of Antimicrobial Agents 27 (2006) 217–223 223
to amoxicillin and tetracycline. Antimicrob Agents Chemother 2001;
45:3253–5.
[54] Takemoto T, Kurihara H, Dahlen G. Characterization of Bacteroides
forsythus isolates. J Clin Microbiol 1997;35:1378–81.
[55] Bahar H, Torun MM, Demirci M, Kocazeybek B. Antimicrobial
resistance and beta-lactamase production of clinical isolates of Pre-
votella and Porphyromonas species. Chemotherapy 2005;51:9–14.
[56] Kahlmeter G, Brown DF, Goldstein FW, et al. European harmoniza-
tion of MIC breakpoints for antimicrobial susceptibility testing of
bacteria. J Antimicrob Chemother 2003;52:145–8.
[57] Rodrigues RM, Goncalves C, Souto R, Feres-Filho EJ, Uzeda M,
Colombo AP. Antibiotic resistance profile of the subgingival micro-
biota following systemic or local tetracycline therapy. J Clin Peri-
odontol 2004;31:420–7.
 
 
 
                                                                                                     
                                                                                                                                                                      
                                                                                                                   Paper 2 
 
 
 
 
 
 
 
 
Proteomic analysis of ampicillin-resistant oral Fusobacterium nucleatum. 
Oral Microbiology Immunology 2008: 23: 1–7 
 
By 
 
M. Al-Haroni, N. Skaug, V. Bakken, P. Cash 
 
 
 
 
 
 
 
 
 
 
 
 
 
Oral Microbiology Immunology 23, Al-Haroni, M.; Skaug, N.; Bakken, V.; Cash P., 
Proteomic analysis of ampicillin-resistant oral Fusobacterium nucleatum, pp. 1-7.  
Copyright 2008 Blackwell Munksgaard. Abstract only. Full-text not available due to publisher 
restrictions. http://dx.doi.org/10.1111/j.1399-302X.2007.00387.x  
 
Proteomic analysis of ampicillinresistant oral Fusobacterium 
nucleatum 
 
Abstract 
 
Introduction: Fusobacterium nucleatum represents one of the predominant anaerobic species 
in the oral microbiota. Penicillin-resistant F. nucleatum have been isolated from intra- and 
extraoral infections. This study aimed to assess ampicillin resistance in F. nucleatum by 
investigating the synthesis of resistance-associated proteins.  
Methods: Ampicillin-resistant and ampicillin-susceptible F. nucleatum isolates were obtained 
from 22 dental plaque samples. Two-dimensional gel electrophoresis and mass spectrometry 
were used to investigate bacterial protein synthesis. Proteins exhibiting statistically significant 
quantitative changes between sensitive and resistant isolates were identified using peptide 
mass mapping and matrix-assisted laser desorption/ionization – time of flight/time of flight 
(MALDI-TOF/TOF) mass spectrometry. 
Results: Twenty-three F. nucleatum isolates were recovered from plaque samples and their 
ampicillin minimum inhibitory concentrations ranged between 0.125 lg/ml and 256 lg/ml. 
Analysis of the bacterial cellular proteins by two-dimensional gel electrophoresis resolved 
154–246 distinct protein spots (mean 212, n = 9). Between 32% and 83% of the protein spots 
were common for the F. nucleatum isolates. Comparisons of the protein profiles of sensitive 
and resistant isolates revealed the presence of a 29 kDa protein and significant increases in the 
synthesis of two proteins at 37 and 46 kDa in the ampicillin-resistant F. nucleatum isolates. 
These proteins were identified as a class D b-lactamase, ATP-binding cassette (ABC) 
transporter ATP-binding protein and enolase, respectively. 
Conclusion: Synthesis of a class D b-lactamase by ampicillin-resistant F. nucleatum isolates 
could complicate antimicrobial treatment because these enzymes might confer resistance to 
many classes of b-lactam antibiotics. The differences observed in protein synthesis between 
ampicillin-resistant and ampicillin-susceptible F. nucleatum may contribute to the antibiotic 
resistance and virulence of these bacteria. 
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Abstract
Objective. Overuse of antimicrobial agents is closely related to an increase in bacterial resistance. A sound knowledge
of appropriate prescribing of antimicrobials among health professionals is thus critical in combating the resistance. The
objectives of this study were to assess the rationale for and patterns of antimicrobial prescriptions by general dental
practitioners in Yemen. Material and Methods. A questionnaire containing 65 closed questions was used for this cross-
sectional study and distributed to 280 dentists in the three major governorates in Yemen. The anonymously completed
questionnaires sought answers to demographic questions and to questions on the therapeutic and prophylactic use
of antimicrobial agents in dentistry. Correct and incorrect answers were defined according to information available in
the current authoritative literature. Each correct answer was given a score of 1 while an incorrect answer scored 0. Thus,
the total score had an attainable range from 0 to 65. Frequencies, means, and associations were assessed statistically.
Results. Out of 181 collected forms (response rate 64.6%), 150 were appropriately completed and used for data analyses.
Penicillins were the most frequently prescribed drugs (72%), followed by spiramycin (10%). It was found that up to 84% of
practitioners were likely to prescribe an antimicrobial agent when there was no clinical indication for such a medication.
Many respondents (70%) would consider antibiotics for at least one of the given non-clinical factors. Conclusions. The
results suggest that dental practitioners in Yemen lack uniformity in the rationale for appropriate prescribing of
antimicrobials to their patients. Consequently, to reduce overuse, there is an urgent need for the dental community in
the country to be informed about evidence-based guidelines and the appropriate use of antimicrobial agents in clinical
dental practice.
Key Words: Antibiotics, general dental, prescription, Yemen
Introduction
Resistance to antimicrobial agents is the ability of
microbes to remain impervious to the inhibitory or
lethal effects of these drugs and this has increased in
conjunction with the ever widening use of antimi-
crobials in recent years. Thus, resistance to all
antimicrobial agents was already noticed within the
first couple of years after they were introduced in
clinical medicine. The prevalence of resistant isolates
and their level of resistance have reached a critical
point, and alarming cases are increasingly being
reported which are also a cause of concern to
dentistry [1,2]. In addition, the continuous emer-
gence of multiresistant species is reported from
different parts of the globe and shows their ability
to tolerate a panel of antibiotics and to cause serious
mortality. This global problem is one of the biggest
challenges facing public health today [3].
Bacterial resistance to antimicrobials is a result of
a complex interplay of several factors [3,4]. The
selective pressure exerted by widespread use of
antimicrobial drugs is regarded as the driving force
behind the evolution of microbial defense mechan-
isms. It has been shown, however, that a significant
reduction in the use of antibiotics can be followed by
a significant reduction in antimicrobial resistance
and it is only through prudent and appropriate use of
these drugs that their efficacy can be prolonged [5].
Misuse of antibiotics can be traced to the pre-
scribers, patient compliance to prescriptions, and the
drug sellers. Physicians’ perceptions of patients’
expectations might influence their prescription of
antibiotics [6] and this is probably also the case with
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dentists. The few published studies on dentists’
knowledge of antibiotic prescription have revealed
that factors other than a sound knowledge might
influence their prescription practices [710]. The
misuse is more widespread when antibiotics are
obtainable without prescriptions and where general
knowledge and beliefs among the public are based
on poor understanding [11]. Furthermore, many
dental infections are mixed infections that provide an
optimum environment for exchange of resistance
determinants between bacterial species, thus result-
ing in even more resistance if combined with
improper use of antimicrobials [12].
The prescribing of antimicrobials in dental prac-
tice is generally considerably less than that in
medical practice [13,14]. However, in England and
Scotland, dentists accounted for about 10% of all
community prescriptions and in the USA, in the
period 199597, for almost 9% of the most com-
monly used antimicrobial agents in Western coun-
tries [2,7]. Furthermore, antimicrobials are the most
common medication prescribed by dental practi-
tioners in developed [15] and developing countries
[16]. Therefore, the contribution by dentistry to
microbial resistance should not be neglected. In line
with this, in 1999 the Fe´deration Dentaire Interna-
tional (World Dental Federation) Commission is-
sued guidelines for appropriate use of antimicrobial
agents to minimize development of resistance in
dentistry [17]. Following other current guidelines
and recommendations for therapeutic and prophy-
lactic use of antimicrobial agents in immunocompe-
tent [18,19] and immunocompromised [20,21]
patients, will also contribute towards reaching this
goal and subsequently will have an influence on
combating resistance emergence.
Recently, we found a significantly higher preva-
lence of resistance to ampicillin and metronidazole
among 18 selected oral microbes from Yemeni dental
patients compared with those in Norway [22]. This
finding prompted the current study, the aim of which
was to assess the knowledge of general dental
practitioners in Yemen in understanding the condi-
tions for appropriate prescribing of antimicrobial
agents to their patients.
Material and methods
Questionnaire
This cross-sectional questionnaire study was per-
formed during the summer of 2004. The question-
naire comprised 65 close-ended questions. The
questionnaire was identical to the one designed
and first used by Palmer et al. [7] with the exception
that the first three questions were omitted: 1) ‘‘Have
you attended any postgraduate courses on antibiotic
prescribing within the past two years?’’, 2) ‘‘Year of
first dental degree’’, and 3) ‘‘Place of qualification’’.
The questionnaire sought answers to the following
11 parameters : (i) gender, (ii) age bands (2130,
3140, 4150, 5160, and above 61 years), (iii)
clinical signs, (iv) antimicrobial treatment of dental
infection (choice of antibiotic, dose and frequency
used, and number of days treated), (v) non-clinical
factors, (vi) choice of antimicrobial agent to dental
infection in the case of patients allergic to penicillin,
(vii) clinical conditions, (viii) treatment procedure
with no relevant medical history, (ix) a relevant
medical history, (x) antibiotic regimen used for
prophylaxis with adult medically compromised
patients (MCPs) not allergic to penicillin, and (xi)
antibiotic regimen used for medically compromised
patients allergic to penicillin. The categories of
questions designated (iii), (v), (vii), and (viii) had
various alternative answers (see Table II) and the
respondents were asked to indicate ‘‘Yes’’ or ‘‘No’’
according to their opinion on each of these answers.
Category (ix), ‘‘A relevant medical history’’, com-
prised 19 medical conditions (see Table III) that
the respondents had to mark according to whether
they thought prophylactic antibiotics were required
or not.
A list of dentists was obtained from the databases
of three pharmaceutical companies that operate in
Yemen. Because there is no postal system in the
country, the questionnaires were distributed by hand
by one of the investigators (M.A-H.) to 280 dentists
working in all the governmental as well as pri-
vate dental clinics in the three major governorates
(Sana’a, Aden, and Taiz). The purpose and impor-
tance of the study were explained to all recipients of
the questionnaire. The questionnaires were collected
later during a maximum of three different visits
before a recipient was reported as a non-respondent.
Data analysis
Response rate and gender distribution were com-
puted. Scores of knowledge were calculated
by giving each correct answer a score of 1 while
an incorrect answer scored 0. Thus, the total know-
ledge score of a questionnaire had an obtainable
range from 0 to 65 based on information in guide-
lines, recommendations, and expert literature
[18,19,23]. This authoritative information defined
correct answers as follows: In the ‘‘Clinical signs’’
category, ‘‘Yes’’ would be a correct answer for
elevated temperature and evidence of systemic
spread, gross or diffuse swelling, difficulty in swal-
lowing, and closure of the eye because of swelling.
Similarly, ‘‘No’’ would be the correct answer for all
answer alternatives in ‘‘Non-clinical factors’’ and
‘‘No relevant medical history’’. Of the 13 alternatives
in ‘‘Clinical conditions’’, ‘‘Yes’’ is a correct answer
only for cellulitis and acute ulcerative gingivitis.
Regarding the need for prophylaxis in MCPs, the
medical conditions considered to be the indications
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for antimicrobial prophylaxis are: previous bacterial
endocarditis, prosthetic heart valves, ventricular
septal defect, rheumatic heart disease, aortic steno-
sis, and radiotherapy to head and neck. Dental
extractions, scaling, and polishing are the dental
procedures requiring prophylaxis in MCPs.
The respondents were grouped according to the
scores gained as having: 1) good knowledge (above
80% correct answers), 2) intermediate knowledge
(between 50% and 80% correct answers), and poor
knowledge (fewer than 50% correct answers). Aver-
age knowledge scores for the question categories
(iii), (v), (vii), (viii), and (ix), respectively, were
expressed as percentages and calculated by dividing
the sum of the scores obtained by the sum of the
maximum possible scores for the given category.
Normal distribution of the data was checked, and
the type of statistical test was chosen accordingly.
For each of the categories of questions, the mean
and the standard deviation were calculated. Signifi-
cant differences with gender as a grouping variable
were tested with the Mann-Whitney U-test. When
age bands were used as grouping variable, the
Kruskal-Wallis test was used for statistical computa-
tion. Differences with a p-value5/0.05 were consid-
ered as statistically significant. All analyses were
conducted using SPSS 12.00 for Windows.
Results
A total of 181 questionnaires were collected, giving a
response rate of 64.6%. Of these, 150 had been
properly completed and were analyzed. Sixty-six
percent of the usable forms were submitted by males.
The mean score was 28.9 with a standard deviation
of 5.6. Test of significance (Mann-Whitney test,
pB/0.001) showed a lower female mean score
than male mean score (27.6, SD 4.6 and 29.57,
SD 5.9, respectively). Group statistics using gender
as a grouping test variable against the different
Table I. Maximum possible scores, ranges, mean and standard deviation (SD) of scores, and respondents’ level of knowledge of the five
categories of questions in the questionnaire
Categories of questions Maximum score Range Mean9/SD Level of knowledge (%)
Clinical signs* 6 06 3.729/1.03 Intermediate (62)
Clinical conditions* 14 014 3.259/1.26 Poor (40)
Non-clinical factors* 5 05 5.999/2.08 Intermediate (65)
Treatment procedure with no relevant medical history* 7 07 3.489/1.40 Poor (49)
Relevant medical history** 19 019 6.509/3.65 Poor (34)
*For details, see Table II; **For details, see Table III.
Table II. Distribution of respondents’ ‘‘Yes’’ and ‘‘No’’ answers regarding clinical signs and conditions, non-clinical factors and no relevant
medical history that require/do not require prophylactic antibiotics
Clinical signs Yes/No Non-clinical factors Yes/No
1. Elevated temperature and evidence of
systemic spread
115/35 1. Patient expectation of a prescription 22/128
2. Localized fluctuant swelling 102/48 2. Pressure of time and workload 36/114
3. Gross or diffuse swelling 135/15 3. Patient’s social history 37/113
4. Unrestricted mouth opening 43/107 4. Uncertainty of diagnosis 42/108
5. Difficulty in swallowing 69/81 5. Where treatment has to be delayed 78/72
6. Closure of the eye owing to swelling 117/33
Clinical conditions Yes/No No relevant medical history Yes/No
1. Acute pulpitis 48/102 1. Extraction
2. Acute periapical infection a) routine 27/123
a) before drainage 105/45 b) surgical 135/15
b) after drainage 94/56 2. Apicectomy 139/11
3. Chronic apical infection 108/42 3. Root canal therapy
4. Pericoronitis 126/24 a) preoperative 42/108
5. Cellulitis 117/33 b) postoperative 52/98
6. Periodontal abscess 124/26 4. Scaling and polishing 52/98
7. Acute ulcerative gingivitis 120/30 5. Restorative treatment 4/146
8. Chronic marginal gingivitis 81/69
9. Sinusitis 123/27
10. Chronic periodontitis 100/50
11. Dry socket 102/48
12. Trismus 49/101
13. Reimplantation of teeth 114/36
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Table III. Relative distribution (%) of respondents according to their opinion on dental treatment and patients with medical conditions requiring antibiotic prophylaxis
Relevant medical conditions Scaling and
polishing (%)
Subgingival class II
fillings (%)
Subgingival class V
fillings (%)
Root canal
therapy (%)
Extractions
(%)
Impressions (%) Seek specialist
advice (%)
1. Diabetes mellitus 50.6 26 22.6 34.6 74.6 17.3 24
2. Hemodialysis patients 26.6 16.6 18 22.6 40.6 12 44
3. Hodgkin’s disease 18.6 12.6 10 12.6 22.6 6 44.6
4. Aids 36 28.6 28 34 38.6 16 50.6
5. Patients on immunosuppressives 40 26 26 32.6 40.6 14 46.6
6. Autoimmune disease patients 16 8.6 8 14.6 26.6 4.6 46
7. Renal transplant patients 38 28.6 30 32 52 16.6 46.6
8. Head and neck irradiated patients 18 10 10 16 30.6 10.6 42.6
9. Patients with prosthetic joints 26.6 16.6 18 24 42.6 10 34
10. History of infective endocarditis 74.6 58.6 58.6 60 82.6 28.6 40
11. Cardiac valve prosthesis 64 52 50.6 54 78 22 42
12. Rheumatic heart disease 60 46.6 44.6 52 76.6 22.6 40.6
13. Aortic stenosis 32 26.6 26.6 31 44 14 52
14. Ventricular septal defect 34 28 26 36 48 14 52.6
15. Coronary bypass surgery 26.6 22.6 22.6 30.6 40 12 52.6
16. Rheumatic fever  no valvular dysfunction 30 22.6 22.6 26.6 40.6 12 44
17. Coronary heart disease 40.6 30.6 32.6 36 48 18 48.6
18. Pacemaker 26.6 22.6 22 26 34.6 12.6 48.6
19. Physiological/functional/innocent murmurs 14.6 14 12.6 18 26.6 8 48
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categories revealed a statistically significant differ-
ence (Mann-Whitney test, p5/0.00) in the prescrip-
tion of antibiotics in relation to clinical diagnosis. No
significant difference was found among age-band
groups (Kruskal-Wallis test). The ranges of scores in
question categories with mean and standard devia-
tion are presented in Table I. The table also shows
the general knowledge of when it is appropriate or
inappropriate to use antibiotics in the different parts
of the questionnaire.
Penicillins were prescribed by 72% as the first
drug of choice for treating dental infections, followed
by spiramycin (10%). Three percent of the respon-
dents prescribed erythromycin and lincomycin, 2%
clindamycin and metronidazole, while other antimi-
crobial agents were prescribed by 5% of the respon-
dents. Many respondents (70%) would consider
antimicrobials for at least one of the given non-
clinical reasons. Table II shows that elevated tem-
perature and evidence of systemic spread, gross or
diffuse swelling, closure of the eye because of
swelling, and localized fluctuant swelling represent
the main clinical signs taken by dentists to indicate
the need to prescribe antibiotics to their patients.
Approximately one-third of the respondents indi-
cated that they would prescribe antimicrobials for
patients with acute pulpitis, and around two-thirds
would consider antimicrobials appropriate for
chronic periodontitis and chronic apical infections.
Table III presents the respondents’ opinions on
dental treatment and patients with medical condi-
tions requiring antibiotic prophylaxis. It reveals that
a history of previous infective endocarditis, followed
by cardiac valve prosthesis are the conditions that
most respondents indicated as requiring antibiotic
prophylaxis in all investigated treatment procedures.
On the other hand, patients with autoimmune
disease and Hodgkin’s disease received little such
attention.
Discussion
The questionnaire investigated the dentists’ know-
ledge of therapeutic and prophylactic antimicrobial
usage in clinical dentistry. This is the first study of its
kind in Yemen. The knowledge of the respondents in
some aspects was better than in others, but a general
lack of uniformity and compliance with the expert
literature [19,23,24] predominated. Palmer et al. [7]
suggested that 29% of antimicrobial usage has no
rational basis. Our findings revealed that the respon-
dents would prescribe antimicrobials on the demand
of patients or their social history, by 15% and 25%,
respectively. Twenty-eight percent of the respon-
dents would prescribe antimicrobials based on no
diagnosis. This figure was found to be only 9% in
England and Scotland [7] but reached 20% in a
study conducted in Kuwait [9]. Lack of time and
pressure of workload, with no clinical background
had an influence on 24% of our respondents when
prescribing antimicrobial agents. It is noticeable that
a large number claimed they would not prescribe
antibiotics after conservative treatment. However,
32% of them believed in the use of antibiotics in
patients presenting with acute pulpitis, which is
proven to be of no benefit at all in such cases [25].
The controversy between the two answers highlights
the misconception of relating clinical observations
and underlying pathological conditions.
The majority of chronic or even acute dental
infections can be successfully treated by eliminating
the source of infection, pulp extirpation, drainage of
abscess, or tooth extraction without the need for
antibiotics. Exceptions are when there is evidence of
systemic involvement and gross, rapid, and diffuse
spread of infection [19]. However, a large proportion
of the surveyed Yemeni dentists indicated they would
prescribe antimicrobial agents for treatment of
several dental clinical conditions for which such
drugs have no justification at all. For example,
72% and 54% would prescribe antibiotics for
chronic apical infections and chronic marginal
gingivitis, respectively. Routine use of antimicrobials
by many respondents was illustrated by their treat-
ment of dry sockets and pericoronitis, where evi-
dence-based practice indicates local treatment alone
as being sufficient [19]. However, in some clinical
situations, e.g. pericoronitis with widespread infec-
tion or systemic involvement [26], prescribing anti-
biotics is justified. Such exceptional situations were
not intercepted by our questionnaire. The general
tendency of respondents to over-prescribe antimi-
crobials may be a consequence of lack of aseptic
techniques, thus a ‘‘just in case’’ principle is prac-
ticed. This opinion would in itself be a justification
for overuse of antibiotics, and such a practice is
totally unacceptable because there is increasing
evidence that it leads to a serious rise in bacterial
resistance [27].
Our results indicate that penicillins are the family
of antimicrobials that most dentists in Yemen would
prescribe for treatment of dental infections. How-
ever, 10% would use a macrolide antimicrobial
(spiramycin) as their first choice in such cases.
This choice is difficult to explain and is not in line
with the practice of dentists in other countries
[10,28].
Participants scored better on clinical signs and
symptoms and on non-clinical factors than they
scored on prophylaxis in MCPs, suggesting that
dentists need to extend their knowledge from just
treating patients’ teeth to treating patients with
teeth. Prophylaxis in MCPs who receive dental
treatment is not always a clear-cut matter, because
different guidelines may have different recommenda-
tions and different regimens exist [23,29]. These
differences may lead to controversy in a subgroup of
medically compromised dental patients, e.g. MCPs
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requiring placement of a rubber dam, in which
antibiotic prophylaxis is mandatory according to
the British Cardiac Society (BCS) guidelines, while
they are neglected in the American Heart Associa-
tion (AHA) guidelines [23]. Clinical judgment might
also influence a dentist’s decision on antimicrobial
coverage in patients with a compromised immune
system, such as AIDS and diabetic patients, who
generally do not require such prophylaxis [23].
Furthermore, the same guidelines could be refused
by one dental school and adopted by another in the
same country, owing to the lack of convincing
scientific background information [30]. These ex-
amples highlight the need for international guide-
lines that are generally agreed on and followed, as
several different opinions might be a gateway to
misuse.
Despite the domination of poor and low inter-
mediate knowledge among respondents, a significant
difference was found in the general knowledge
between genders with regard to antimicrobial pre-
scription in acute pulpitis, acute and chronic peria-
pical infection, cellulitis, pericoronitis, periodontal
abscess, acute ulcerative gingivitis, chronic marginal
gingivitis, chronic periodontitis, sinusitis, and dry
socket, in which females scored less than males. This
favorable and advantageous male prescription pat-
tern might be due to males being more confident
than females. Or females, besides being introduced
relatively recently to the labor force, might be more
afraid of being accused of infection sequelae of
dental treatment.
Our findings indicate that the scientific basis for
prescribing antimicrobial agents was neglected by
the majority of the respondents. This situation is not
surprising as similar findings were reported among
other health professionals in Yemen [31] and by
general dental practitioners in other countries
[7,9,10]. An exception is a study conducted in
Norway some years ago [32]. Inferences from our
study and similar studies raise questions about
whether it is lack of, or ignorance of guidelines that
lies behind antibiotics overuse. Such irrational use of
antibiotics can be corrected by arranging an audit of
clinical antibiotic prescription in dentistry, which is
reported to improve general dental practitioners’
attitudes to prescribing antimicrobials by, in some
circumstances, 50% [33,34]. It is also worth men-
tioning here that general medical practitioners were
found to prescribe more antibiotics and more broad-
spectrum ones than did dentists when dealing with
acute dental emergencies [35]. The use of antimi-
crobial agents will select for resistant isolates, and
if this use is unnecessary, the situation will
be worsened [5]. Nowadays it is not unusual to see
an isolate with multidrug resistance or a ‘‘superbug’’
that does not respond to any antibiotic.
No official records indicate how many dentists
there are in Yemen. However, we gained access to a
list of all established governmental hospitals as well
as private dental clinics. Dentistry is considered a
relatively new professional discipline in this country,
the first dental college having been established in
1994. Before that, dentists gained their degree
abroad, mainly from eastern European countries
and neighboring Arab universities. Yemeni dentists
are not willing to reveal their professional identity by
giving information about the place and year of their
graduation; furthermore, no postgraduate courses
on the prescribing of antimicrobials are offered to
them in Yemen. On these bases, the first three
questions in the original questionnaire of Palmer
et al. [7] were omitted in our study.
One hundred and fifty usable forms out of
280 distributed (53.5% usable) and 181 collected
(82.8% usable) forms were analyzed. This may raise
questions about the representativeness of the data for
Yemeni dentists in general and whether the non-
respondents might have affected the study outcomes
if they had responded. However, the demographic
features of the non-respondents or of the 31 dentists
that returned partially completed questionnaires
yielded no new information, compared to the usable
ones. In fact, investigating health workers’ knowl-
edge is considered a sensitive issue. This might
partly explain the non-respondents’ refusal to give
information about their reasons for not complying,
when further approached. It is probable that non-
respondents might have an even poorer knowledge
than those who responded. The low response rates
among health practitioners are not uncommon [36].
We addressed the importance of the study and the
study subjects were reminded at two subsequent
visits, but not more than about two-thirds of them
responded positively. This lack of responsiveness
might be due to high workload, loss of the ques-
tionnaire, or even lack of interest [37].
In conclusion, our study is the first survey to date
among Yemeni dentists. The findings, being repre-
sentative of about 53.6% of all general dental
practitioners in Yemen and studied in the light of
the authoritative international literature in the field,
indicate that too few Yemeni dentists have a good
knowledge of antimicrobial indications and contra-
indications. A consequence will be overuse of anti-
microbial agents, which is most probably one
explanation for the greater prevalence of resistant
subgingival species among dental patients in Yemen,
when compared with Norway [22]. Consequently, it
is a matter of urgency that the dental community in
Yemen is informed about the accepted current
antibiotic prescription guidelines and the related
evidence-based clinical practice. This is significant,
since the implication of these recommendations
will be one important step towards restricting
the inappropriate use of antimicrobial agents in
this country.
M. Al-Haroni & N. Skaug 279
Acknowledgments
This study was supported by the Norwegian Loan
Fund for Education.
References
[1] Sweeney LC, Dave J, Chambers PA, Heritage J. Antibiotic
resistance in general dental practice: a cause for concern?
J Antimicrob Chemother 2004;/53:/56776.
[2] Pallasch TJ. Antibiotic resistance. Dent Clin North Am
2003;/47:/62339.
[3] WHO report on infectious diseases. Wkly Epidemiol Rec
1999;74:279.
[4] Byarugaba DK. A view on antimicrobial resistance in
developing countries and responsible risk factors. Int J
Antimicrob Agents 2004;/24:/10510.
[5] Committee SMA. The path of least resistance. London:
Department of Health; 1998.
[6] Macfarlane J, Holmes W, Macfarlane R, Britten N. Influence
of patients’ expectations on antibiotic management of acute
lower respiratory tract illness in general practice: question-
naire study. Br Med J 1997;/315:/12114.
[7] Palmer NO, Martin MV, Pealing R, Ireland RS, Roy K,
Smith A, et al. Antibiotic prescribing knowledge of National
Health Service general dental practitioners in England and
Scotland. J Antimicrob Chemother 2001;/47:/2337.
[8] Dailey YM, Martin MV. Are antibiotics being used appro-
priately for emergency dental treatment? Br Dent J 2001;/
191:/3913.
[9] Salako NO, Rotimi VO, Adib SM, Al-Mutawa S. Pattern of
antibiotic prescription in the management of oral diseases
among dentists in Kuwait. J Dent 2004;/32:/5039.
[10] Jaunay T, Sambrook P, Goss A. Antibiotic prescribing
practices by South Australian general dental practitioners.
Aust Dent J 2000;45:17986; quiz 214.
[11] Buke C, Hosgor-Limoncu M, Ermertcan S, Ciceklioglu M,
Tuncel M, Kose T, et al. Irrational use of antibiotics among
university students. J Infect 2005;/51:/1359.
[12] Kolenbrander PE, Andersen RN, Blehert DS, Egland PG,
Foster JS, Palmer RJ, Jr. Communication among oral
bacteria. Microbiol Mol Biol Rev 2002;/66:/486505.
[13] Carrotte P. Endodontics: Part 3. Treatment of endodontic
emergencies. Br Dent J 2004;/197:/299305.
[14] Slots J, Ting M. Systemic antibiotics in the treatment of
periodontal disease. Periodontology 2000 2002;/28:/10676.
[15] Ciancio S, Reynard A, Zielezny M, Mather M. A survey of
drug prescribing practices of dentists. NY State Dent J 1989;/
55:/2931.
[16] Ogunbodede EO, Fatusi OA, Folayan MO, Olayiwola G.
Retrospective survey of antibiotic prescriptions in dentistry.
J Contemp Dent Pract 2005;/6:/6471.
[17] Samaranayake LP, Johnson NW. Guidelines for the use of
antimicrobial agents to minimise development of resistance.
Int Dent J 1999;/49:/18995.
[18] Seymour RA, Whitworth JM. Antibiotic prophylaxis for
endocarditis, prosthetic joints, and surgery. Dent Clin North
Am 2002;/46:/63551.
[19] Palmer NA. Revisiting the role of dentists in prescribing
antibiotics. Dent Update 2003;/30:/5704.
[20] Dajani AS, Taubert KA, Wilson W, Bolger AF, Bayer A,
Ferrieri P, et al. Prevention of bacterial endocarditis:
recommendations by the American Heart Association. Clin
Infect Dis 1997;/25:/144858.
[21] Pallasch TJ. Antibiotic prophylaxis: problems in paradise.
Dent Clin North Am 2003;/47:/66579.
[22] Al-Haroni MH, Skaug N, Al-Hebshi NN. Prevalence of
subgingival bacteria resistant to aminopenicillins and me-
tronidazole in dental patients from Yemen and Norway. Int J
Antimicrob Agents 2006;/27:/21723.
[23] Tong DC, Rothwell BR. Antibiotic prophylaxis in dentistry:
a review and practice recommendations. J Am Dent Assoc
2000;/131:/36674.
[24] Addy M, Martin MV. Systemic antimicrobials in the treat-
ment of chronic periodontal diseases: a dilemma. Oral Dis
2003;/9(Suppl 1):/3844.
[25] Keenan JV, Farman AG, Fedorowicz Z, Newton JT. Anti-
biotic use for irreversible pulpitis. Cochrane Database Syst
Rev 2005:CD004969.
[26] National Clinical Guidelines. London: Faculty of Dental
Surgery; 1997.
[27] Larrabee T. Prescribing practices that promote antibiotic
resistance: strategies for change. J Pediatr Nurs 2002;/17:/
12632.
[28] Palmer NO, Martin MV, Pealing R, Ireland RS. An analysis
of antibiotic prescriptions from general dental practitioners
in England. J Antimicrob Chemother 2000;/46:/10335.
[29] Palmer NA, Pealing R, Ireland RS, Martin MV. A study
of prophylactic antibiotic prescribing in National Health
Service general dental practice in England. Br Dent J 2000;/
189:/436.
[30] Longman LP, Martin NV, Field EA, Milosevic A, Randall C,
Davies M, et al. Cause for concern? Br Dent J 2004;/197:/115.
[31] Al-Maktari MT, Bassiouny HK. Malaria status in Al-
Hodeidah Governorate, Republic of Yemen. Part II: Human
factors causing the persistence of chloroquine resistant P.
falciparum local strain. J Egypt Soc Parasitol 2003;/33:/
82939.
[32] Preus HR, Albandar JM, Gjermo P. Antibiotic prescribing
practices among Norwegian dentists. Scand J Dent Res
1992;/100:/2325.
[33] Steed M, Gibson J. An audit of antibiotic prescribing in
general dental practice. Prim Dent Care 1997;/4:/6670.
[34] Palmer NA, Dailey YM, Martin MV. Can audit improve
antibiotic prescribing in general dental practice? Br Dent J
2001;/191:/2535.
[35] Anderson R, Calder L, Thomas DW. Antibiotic prescribing
for dental conditions: general medical practitioners and
dentists compared. Br Dent J 2000;/188:/398400.
[36] McMahon SR, Iwamoto M, Massoudi MS, Yusuf HR,
Stevenson JM, David F, et al. Comparison of e-mail, fax,
and postal surveys of pediatricians. Pediatrics 2003;/111:/
e299303.
[37] Key C, Layton D, Shakir SA. Results of a postal survey of
the reasons for non-response by doctors in a prescription
event monitoring study of drug safety. Pharmacoepidemiol
Drug Safety 2002;/11:/1438.
280 Antimicrobials prescription knowledge
                                       
 
                                                   
                                                   Paper 4 
 
 
 
 
 
 
 
 
Incidence of antibiotic prescribing in dental practice in Norway and its 
contribution to national consumption. Journal of Antimicrobial 
Chemotherapy (2007) 59, 1161–1166 
 
By 
 
Mohammed Al-Haroni and Nils Skaug 
 
Journal of Antimicrobial Chemotherapy 59(6), Mohammed Al-Haroni and Nils Skaug, 
Incidence of antibiotic prescribing in dental practice in Norway and its contribution to 
national consumption, pp. 1161–1166. Copyright The Author 2007. Published by Oxford 
University Press on behalf of the British Society for Antimicrobial Chemotherapy. Abstract 
only. Full-text not available due to publisher restrictions. 
http://dx.doi.org/10.1093/jac/dkm090  
 
 
Incidence of antibiotic prescribing in dental practice in Norway 
and its contribution to national consumption 
  
 
Abstract 
 
 
Objectives: To assess dentistry-based utilization of the 11 antibiotics prescribed by dentists in 
Norway and its relative contribution to national outpatient consumption and to determine the 
relationship between numbers of prescriptions and the consumption of these antibiotics. 
Methods: Data on national antibiotic prescriptions by dentists in 2004 and 2005 were used. 
Consumption of the antibiotics was expressed using WHO defined daily doses (DDDs), 
DDDs per 1000 inhabitants per day (DIDs) and numbers of prescriptions per 1000 inhabitants 
(PIDs).  
Results: Analysis of 268 834 prescriptions issued by 4765 dentists showed that the dentists’ 
prescriptions contributed 8% of the total national consumption of the 11 antibiotics and 
13.5%, 2.8% and 1.2% of the national b-lactam penicillins, macrolides and lincosamides and 
tetracyclines utilization, respectively. The dentists’ contributions to the national 
phenoxymethylpenicillin, spiramycin and metronidazole consumptions were considerably 
higher (_13.2%) than for the other prescribed antibiotics (_8.6%). There was a strong positive 
correlation between numbers of DDDs and numbers of prescriptions and between DIDs and 
numbers of PIDs. 
Conclusions: Reliance of Norwegian dentists on phenoxymethylpenicillin as their first choice 
suggests a low prevalence of antibiotic resistance among oral bacteria in Norway. Norwegian 
dentists prefer to prescribe narrow-spectrum antibiotics; their prescribing is conservative and 
relatively low compared with that of physicians. 
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